index,title,abstract,Master Ref#,PubMed ID,Journal,Primary Author,Publication Year,Volume / Issue,Pages,Priority Journal,PubMed ID:,Full Reference:,"Study Outcome ($/QALY, $/DALY, Both):",Study Country:,Disease Classification:,Intervention Type(s):,Intervention Phrase vs. Comparator Phrase:,Target Characteristics:,Max Target Age:,Min Target Age:,Target Genders:,Review:,Time Horizon:,Discounting Rate (Costs):,Discounting Rate (QALYs):,Incremental Cost-Effectiveness Ratio (Original currency and year):,Currency Country:,Currency Year:,Incremental Cost-Effectiveness Ratio (Converted to current $USD):
28401,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Inhaled bronchodilator and corticosteroid vs. None,stage III & IV,Not Stated,Not Stated,Female,Full,,3.00,3.00,24687.5,United States,2005,32715.8
28402,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Influenza vaccine vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,2758,United States,2005,3654.89
28403,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Smoking cessation vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,5059,United States,2005,6704.17
28404,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Population salt reduction by 30% to combat cardiovascular disease vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,293,United States,2005,388.28
28405,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Detection of high risk individuals through cholesterol testing vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,567,United States,2005,751.39
28406,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Detection of high rish individuals- cholesterol >240mg/dL vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,8174,United States,2005,10832.16
28407,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Detection of high rish individuals- hypertension >140mmHg vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,3855,United States,2005,5108.63
28408,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical","Combination of health education, legislation with food industry, detection and treatment of high risk individuals based on blood pressure, serum cholesterol, and absolute risk thresholds vs. None",Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,1879,United States,2005,2490.05
28409,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical","Combination of health education, legislation with food industry, detection and treatment of high risk individuals based on blood pressure, serum cholesterol, and absolute risk threshold above 5% vs. None",Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,4140,United States,2005,5486.32
28410,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Aspirin for acute ischemic stroke vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,120526,United States,2005,159720.71
28411,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Beta blocker for acute myocardial infarction vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,20039,United States,2005,26555.63
28412,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",ACE inhibitor for acute myocardial infarction vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,11607,United States,2005,15381.56
28413,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Organised stroke unit care vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,28250,United States,2005,37436.82
28414,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",ACE inhibitor for coronary heart failure vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,1100,United States,2005,1457.72
28415,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Aspirin for post-acute ischemic heart disease vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,2975,United States,2005,3942.46
28416,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Aspirin for acute myocardial infarction vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,3388,United States,2005,4489.77
28417,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Thrombolysis with streptokinase vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,7138,United States,2005,9459.26
28418,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Beta blocker for coronary heart failure vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,445,United States,2005,589.71
28419,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Statin for post-acute ischemic heart disease vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,7864,United States,2005,10421.35
28420,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Exercise training for coronary heart failure vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,402,United States,2005,532.73
28421,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Aspirin for actue myocardial infarction + streptokinase vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,4243,United States,2005,5622.81
28422,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Aspirin + beta blocker + ACE inhibitor + streptokinase for acute myocardial infarction vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,3772,United States,2005,4998.64
28423,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Beta blocker for post-acute myocardial infarction vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,1117,United States,2005,1480.25
28424,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",ACE inhibitor for post-acute ischemic heart disease vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,1045,United States,2005,1384.83
28425,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Primary percutaneous transluminal coronary angioplasty (PTCA) vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,3416,United States,2005,4526.87
28426,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Aspirin for post acute ischemic stroke vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,1164,United States,2005,1542.53
28427,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Beta blocker + aspirin for post-acute ischemic heart disease vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,887,United States,2005,1175.45
28428,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Cardiac rehabilitation vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,50,United States,2005,66.26
28429,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Aspirin for actue myocardial infarction + primary percutaneous transluminal coronary angioplasty (PTCA) vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,2972,United States,2005,3938.49
28430,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Aspirin + beta blocker + ACE inhibitor for acute myocardial infarction + primary percutaneous transluminal coronary angioplasty (PTCA) vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,2846,United States,2005,3771.51
28431,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Beta blocker + aspirin + statin for post-acute ischemic heart disease vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,2884,United States,2005,3821.87
28432,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Diuretic for coronary heart failure vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,194,United States,2005,257.09
28433,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Statin for post-acute ischemic stroke vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,1762,United States,2005,2335
28434,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",ACE inhibitor + diuretic for post stroke vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,1226,United States,2005,1624.69
28435,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",All heart failure interventions vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,383,United States,2005,507.55
28436,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",All secondary pharmacologic prevention for acute myocardial infarction vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,2116,United States,2005,2804.12
28437,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Statin for stroke and myocardial infarction vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,2938,United States,2005,3893.43
28438,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Aspirin + beta blocker + statin for myocardial infarction & stroke vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,2303,United States,2005,3051.93
28439,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",All secondary prevention for stroke vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,1158,United States,2005,1534.58
28440,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Lipid control vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,17311,United States,2005,22940.49
28441,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Blood pressure control vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,8562,United States,2005,11346.34
28442,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Conventional glycemic control vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,12496,United States,2005,16559.66
28443,Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis,"To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.Cost effectiveness analysis based on epidemiological modelling.101 intervention strategies relating to nine major clusters of non-communicable disease: depression, heavy alcohol use, tobacco use, cataracts, breast cancer, cervical cancer, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes.Mexican data sources were used for most key input parameters, including administrative registries; disease burden and population estimates; household surveys; and drug price databases. These sources were supplemented as needed with estimates for Mexico from the WHO-CHOICE unit cost database or with estimates extrapolated from the published literature.Population health outcomes, measured in disability adjusted life years (DALYs); costs in 2005 international dollars ($Int); and costs per DALY.Across 101 intervention strategies examined in this study, average yearly costs at the population level would range from around =$Int1m (such as for cataract surgeries) to >$Int1bn for certain strategies for primary prevention in cardiovascular disease. Wide variation also appeared in total population health benefits, from <1000 DALYs averted a year (for some components of cancer treatments or aspirin for acute ischaemic stroke) to >300,000 averted DALYs (for aggressive combinations of interventions to deal with alcohol use or cardiovascular risks). Interventions in this study spanned a wide range of average cost effectiveness ratios, differing by more than three orders of magnitude between the lowest and highest ratios. Overall, community and public health interventions such as non-personal interventions for alcohol use, tobacco use, and cardiovascular risks tended to have lower cost effectiveness ratios than many clinical interventions (of varying complexity). Even within the community and public health interventions, however, there was a 200-fold difference between the most and least cost effective strategies examined. Likewise, several clinical interventions appeared among the strategies with the lowest average cost effectiveness ratios-for example, cataract surgeries.Wide variations in costs and effects exist within and across intervention categories. For every major disease area examined, at least some strategies provided excellent value for money, including both population based and personal interventions.",2012-99-08799,22389335,BMJ,Joshua A Salomon,2012,344 /,e355,No,22389335,"Joshua A Salomon; Natalie Carvalho; Cristina Guti?rrez-Delgado; Ricardo Orozco; Anna Mancuso; Daniel R Hogan; Diana Lee; Yuki Murakami; Lakshmi Sridharan; Mar?a Elena Medina-Mora; Eduardo Gonz?lez-Pier; Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis, BMJ, ; 344 ():0959-8138; e355",DALY,Mexico,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Immunization, Legislation / Regulation, Medical Procedure, Pharmaceutical, Screening, Surgical",Intensive glycemic control vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,3.00,3.00,13632,United States,2005,18065.09
28444,Evaluation of current guthrie TSH cut-off point in Iran congenital hypothyroidism screening program: a cost-effectiveness analysis,"The threshold of thyroid-stimulating hormone (TSH) in current screening for congenital hypothyroidism (CH) from the heel prick test is 5 mU/l. This study uses cost-effective analysis to evaluate increasing the threshold to minimize false-positive results and recall rates.Cost of screening, diagnosis and treatment, education, and care of mentally retarded patients were gathered from the Ministry of Health State Welfare Organization and Department of Education in Tehran. Screening data were obtained from 34,007 neonates in the Central Health Laboratory of Tehran University of Medical Sciences in 2009. Sensitivity analysis and calculation of confidence interval for incremental costs and effects (gained disability adjusted life years - DALYs) and incremental cost-effectiveness ratios (ICER) were performed by Monte Carlo simulation with Ersatz software.ICER for screening programs with different TSH cut-off points versus no screening was similar, and approximately -4.5 ? 0.2 thousand US dollars per gained DALY. In the proposed cohort (10,000 neonates), gained DALYs were 316 ? 50 for a cut off point of 5 mU/l, 251 ? 40 for 10 mU/l, 146 ? 23 for 15 mU/l, and 113 ? 18 for a cut-off point of 20 mU/l. Sensitivity analysis showed that the model remained the same when the input parameters were changed.This study demonstrates that the current threshold of TSH in the national CH screening program in terms of cost-effectiveness is the most appropriate threshold. However, more studies are needed to examine new strategies and methods to reduce recall rates and related consequences such as repeated thyroid testing in neonates.",2012-99-08778,22369300,Arch Iran Med,Ahmad Reza Shamshiri,2012,15 /,136-41,No,22369300,"Ahmad Reza Shamshiri; Shahin Yarahmadi; Mohammad Hossein Forouzanfar; Ali Akbar Haghdoost; Gholamreza Hamzehloo; Kourosh Holakouie Naieni; Evaluation of current guthrie TSH cut-off point in Iran congenital hypothyroidism screening program: a cost-effectiveness analysis, Arch Iran Med , ; 15 ():1029-2977; 136-41",DALY,Iran,Not Stated,Screening,"Congenital hypothyroidism screening with thyroid-stimulating hormone (TSH), cut-off point= 10mU/l vs. None",Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,-4580.06,United States,2008,-5505.59
28445,Potential cost-effectiveness of universal access to modern contraceptives in Uganda,"Over two thirds of women who need contraception in Uganda lack access to modern effective methods. This study was conducted to estimate the potential cost-effectiveness of achieving universal access to modern contraceptives in Uganda by implementing a hypothetical new contraceptive program (NCP) from both societal and governmental (Ministry of Health (MoH)) perspectives.A Markov model was developed to compare the NCP to the status quo or current contraceptive program (CCP). The model followed a hypothetical cohort of 15-year old girls over a lifetime horizon. Data were obtained from the Uganda National Demographic and Health Survey and from published and unpublished sources. Costs, life expectancy, disability-adjusted life expectancy, pregnancies, fertility and incremental cost-effectiveness measured as cost per life-year (LY) gained, cost per disability-adjusted life-year (DALY) averted, cost per pregnancy averted and cost per unit of fertility reduction were calculated. Univariate and probabilistic sensitivity analyses were performed to examine the robustness of results. Mean discounted life expectancy and disability-adjusted life expectancy (DALE) were higher under the NCP vs. CCP (28.74 vs. 28.65 years and 27.38 vs. 27.01 respectively). Mean pregnancies and live births per woman were lower under the NCP (9.51 vs. 7.90 and 6.92 vs. 5.79 respectively). Mean lifetime societal costs per woman were lower for the NCP from the societal perspective ($1,949 vs. $1,987) and the MoH perspective ($636 vs. $685). In the incremental analysis, the NCP dominated the CCP, i.e. it was both less costly and more effective. The results were robust to univariate and probabilistic sensitivity analysis.Universal access to modern contraceptives in Uganda appears to be highly cost-effective. Increasing contraceptive coverage should be considered among Uganda's public health priorities.",2012-02-08771,22363480,PLoS One,Joseph B Babigumira,2012,7 /,e30735,No,22363480,"Joseph B Babigumira; Andy Stergachis; David L Veenstra; Jacqueline S Gardner; Joseph Ngonzi; Peter Mukasa-Kivunike; Louis P Garrison; Potential cost-effectiveness of universal access to modern contraceptives in Uganda, PLoS One , ; 7 ():1932-6203; e30735",DALY,Uganda,Not Stated,Legislation / Regulation,Universal access to modern contraceptives vs. Standard/Usual Care- current contraceptive program,Not Stated,15 Years,15 Years,Female,Full,,3.00,3.00,-105.11,United States,2010,-124.75
28446,Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia,"Evidence on the cost and cost-effectiveness of treatment of multidrug-resistant tuberculosis (MDR-TB) is limited, and no published data are available from former Soviet Union countries, where rates of MDR-TB are highest globally. We evaluated the cost and cost-effectiveness of MDR-TB treatment in Estonia and Russia (Tomsk Oblast), comparing cohorts enrolled on treatment according to World Health Organization (WHO) guidelines in 2001 and 2002 with cohorts treated in previous years. Costs were assessed from a health system perspective in 2003 US$; effects were measured as cures, deaths averted and disability-adjusted life-years (DALYs) averted. Cure rates when WHO guidelines were followed were 61% (90 out of 149) in Estonia and 76% (76 out of 100) in Tomsk Oblast, with a cost per patient treated of US$8,974 and US$10,088, respectively. Before WHO guidelines were followed, cure rates were 52% in Estonia and 15% in Tomsk Oblast; the cost per patient treated was US$4,729 and US$2,282, respectively. Drugs and hospitalisation accounted for 69-90% of total costs. The cost per DALY averted by treatment following WHO guidelines was US$579 (range US$297-US$902) in Estonia and US$429 (range US$302-US$546) in Tomsk Oblast. Treatment of patients with MDR-TB can be cost-effective, but requires substantial additional investment in tuberculosis control in priority countries.",2012-99-09236,22362862,Eur Respir J,Katherine Floyd,2012,40 / 1,133-42,No,22362862,"Katherine Floyd; Raymond Hutubessy; Kai Kliiman; Rosella Centis; Nina Khurieva; Wieslaw Jakobowiak; Manfred Danilovits; Genadi Peremitin; Salmaan Keshavjee; Giovanni Battista Migliori; Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia, Eur Respir J, ; 40(1):0903-1936; 133-42",DALY,Estonia,Not Stated,Pharmaceutical,Multidrug-resistant treatment as per WHO guidelines vs. Standard/Usual Care- (before WHO guidelines),Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,579,United States,2003,814.41
28447,Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia,"Evidence on the cost and cost-effectiveness of treatment of multidrug-resistant tuberculosis (MDR-TB) is limited, and no published data are available from former Soviet Union countries, where rates of MDR-TB are highest globally. We evaluated the cost and cost-effectiveness of MDR-TB treatment in Estonia and Russia (Tomsk Oblast), comparing cohorts enrolled on treatment according to World Health Organization (WHO) guidelines in 2001 and 2002 with cohorts treated in previous years. Costs were assessed from a health system perspective in 2003 US$; effects were measured as cures, deaths averted and disability-adjusted life-years (DALYs) averted. Cure rates when WHO guidelines were followed were 61% (90 out of 149) in Estonia and 76% (76 out of 100) in Tomsk Oblast, with a cost per patient treated of US$8,974 and US$10,088, respectively. Before WHO guidelines were followed, cure rates were 52% in Estonia and 15% in Tomsk Oblast; the cost per patient treated was US$4,729 and US$2,282, respectively. Drugs and hospitalisation accounted for 69-90% of total costs. The cost per DALY averted by treatment following WHO guidelines was US$579 (range US$297-US$902) in Estonia and US$429 (range US$302-US$546) in Tomsk Oblast. Treatment of patients with MDR-TB can be cost-effective, but requires substantial additional investment in tuberculosis control in priority countries.",2012-99-09236,22362862,Eur Respir J,Katherine Floyd,2012,40 / 1,133-42,No,22362862,"Katherine Floyd; Raymond Hutubessy; Kai Kliiman; Rosella Centis; Nina Khurieva; Wieslaw Jakobowiak; Manfred Danilovits; Genadi Peremitin; Salmaan Keshavjee; Giovanni Battista Migliori; Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia, Eur Respir J, ; 40(1):0903-1936; 133-42",DALY,Russia,Not Stated,Pharmaceutical,Multidrug-resistant treatment as per WHO guidelines vs. Standard/Usual Care- (before WHO guidelines),Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,429,United States,2003,603.42
28448,Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050,"Antiretroviral Treatment (ART) significantly reduces HIV transmission. We conducted a cost-effectiveness analysis of the impact of expanded ART in South Africa.We model a best case scenario of 90% annual HIV testing coverage in adults 15-49 years old and four ART eligibility scenarios: CD4 count <200 cells/mm(3) (current practice), CD4 count <350, CD4 count <500, all CD4 levels. 2011-2050 outcomes include deaths, disability adjusted life years (DALYs), HIV infections, cost, and cost per DALY averted. Service and ART costs reflect South African data and international generic prices. ART reduces transmission by 92%. We conducted sensitivity analyses.Expanding ART to CD4 count <350 cells/mm(3) prevents an estimated 265,000 (17%) and 1.3 million (15%) new HIV infections over 5 and 40 years, respectively. Cumulative deaths decline 15%, from 12.5 to 10.6 million; DALYs by 14% from 109 to 93 million over 40 years. Costs drop $504 million over 5 years and $3.9 billion over 40 years with breakeven by 2013. Compared with the current scenario, expanding to <500 prevents an additional 585,000 and 3 million new HIV infections over 5 and 40 years, respectively. Expanding to all CD4 levels decreases HIV infections by 3.3 million (45%) and costs by $10 billion over 40 years, with breakeven by 2023. By 2050, using higher ART and monitoring costs, all CD4 levels saves $0.6 billion versus current; other ART scenarios cost $9-194 per DALY averted. If ART reduces transmission by 99%, savings from all CD4 levels reach $17.5 billion. Sensitivity analyses suggest that poor retention and predominant acute phase transmission reduce DALYs averted by 26% and savings by 7%.Increasing the provision of ART to <350 cells/mm3 may significantly reduce costs while reducing the HIV burden. Feasibility including HIV testing and ART uptake, retention, and adherence should be evaluated.",2012-99-08744,22348000,PLoS One,Reuben Granich,2012,7 /,e30216,No,22348000,"Reuben Granich; James G Kahn; Rod Bennett; Charles B Holmes; Navneet Garg; Celicia Serenata; Miriam Lewis Sabin; Carla Makhlouf-Obermeyer; Christina De Filippo Mack; Phoebe Williams; Louisa Jones; Caoimhe Smyth; Kerry A Kutch; Lo Ying-Ru; Marco Vitoria; Yves Souteyrand; Siobhan Crowley; Eline L Korenromp; Brian G Williams; Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050, PLoS One , ; 7 ():1932-6203; e30216",DALY,South Africa,Not Stated,Pharmaceutical,Expanding antiretroviral treatment (ART) to CD4 count <350 + current prevention vs. Standard/Usual Care- Expanding antiretroviral treatment (ART) to CD4 count <200 + current prevention,Not Stated,Not Stated,Not Stated,"Female, Male",Full,", 5 yrs",3.00,3.00,-245.8,United States,2010,-291.74
28449,Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050,"Antiretroviral Treatment (ART) significantly reduces HIV transmission. We conducted a cost-effectiveness analysis of the impact of expanded ART in South Africa.We model a best case scenario of 90% annual HIV testing coverage in adults 15-49 years old and four ART eligibility scenarios: CD4 count <200 cells/mm(3) (current practice), CD4 count <350, CD4 count <500, all CD4 levels. 2011-2050 outcomes include deaths, disability adjusted life years (DALYs), HIV infections, cost, and cost per DALY averted. Service and ART costs reflect South African data and international generic prices. ART reduces transmission by 92%. We conducted sensitivity analyses.Expanding ART to CD4 count <350 cells/mm(3) prevents an estimated 265,000 (17%) and 1.3 million (15%) new HIV infections over 5 and 40 years, respectively. Cumulative deaths decline 15%, from 12.5 to 10.6 million; DALYs by 14% from 109 to 93 million over 40 years. Costs drop $504 million over 5 years and $3.9 billion over 40 years with breakeven by 2013. Compared with the current scenario, expanding to <500 prevents an additional 585,000 and 3 million new HIV infections over 5 and 40 years, respectively. Expanding to all CD4 levels decreases HIV infections by 3.3 million (45%) and costs by $10 billion over 40 years, with breakeven by 2023. By 2050, using higher ART and monitoring costs, all CD4 levels saves $0.6 billion versus current; other ART scenarios cost $9-194 per DALY averted. If ART reduces transmission by 99%, savings from all CD4 levels reach $17.5 billion. Sensitivity analyses suggest that poor retention and predominant acute phase transmission reduce DALYs averted by 26% and savings by 7%.Increasing the provision of ART to <350 cells/mm3 may significantly reduce costs while reducing the HIV burden. Feasibility including HIV testing and ART uptake, retention, and adherence should be evaluated.",2012-99-08744,22348000,PLoS One,Reuben Granich,2012,7 /,e30216,No,22348000,"Reuben Granich; James G Kahn; Rod Bennett; Charles B Holmes; Navneet Garg; Celicia Serenata; Miriam Lewis Sabin; Carla Makhlouf-Obermeyer; Christina De Filippo Mack; Phoebe Williams; Louisa Jones; Caoimhe Smyth; Kerry A Kutch; Lo Ying-Ru; Marco Vitoria; Yves Souteyrand; Siobhan Crowley; Eline L Korenromp; Brian G Williams; Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050, PLoS One , ; 7 ():1932-6203; e30216",DALY,South Africa,Not Stated,Pharmaceutical,Expanding antiretroviral treatment (ART) to CD4 count <500 + current prevention vs. Expanding antiretroviral treatment (ART) to CD4 count <350 + current prevention,Not Stated,Not Stated,Not Stated,"Female, Male",Full,", 5 yrs",3.00,3.00,-33.53,United States,2010,-39.8
28450,Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050,"Antiretroviral Treatment (ART) significantly reduces HIV transmission. We conducted a cost-effectiveness analysis of the impact of expanded ART in South Africa.We model a best case scenario of 90% annual HIV testing coverage in adults 15-49 years old and four ART eligibility scenarios: CD4 count <200 cells/mm(3) (current practice), CD4 count <350, CD4 count <500, all CD4 levels. 2011-2050 outcomes include deaths, disability adjusted life years (DALYs), HIV infections, cost, and cost per DALY averted. Service and ART costs reflect South African data and international generic prices. ART reduces transmission by 92%. We conducted sensitivity analyses.Expanding ART to CD4 count <350 cells/mm(3) prevents an estimated 265,000 (17%) and 1.3 million (15%) new HIV infections over 5 and 40 years, respectively. Cumulative deaths decline 15%, from 12.5 to 10.6 million; DALYs by 14% from 109 to 93 million over 40 years. Costs drop $504 million over 5 years and $3.9 billion over 40 years with breakeven by 2013. Compared with the current scenario, expanding to <500 prevents an additional 585,000 and 3 million new HIV infections over 5 and 40 years, respectively. Expanding to all CD4 levels decreases HIV infections by 3.3 million (45%) and costs by $10 billion over 40 years, with breakeven by 2023. By 2050, using higher ART and monitoring costs, all CD4 levels saves $0.6 billion versus current; other ART scenarios cost $9-194 per DALY averted. If ART reduces transmission by 99%, savings from all CD4 levels reach $17.5 billion. Sensitivity analyses suggest that poor retention and predominant acute phase transmission reduce DALYs averted by 26% and savings by 7%.Increasing the provision of ART to <350 cells/mm3 may significantly reduce costs while reducing the HIV burden. Feasibility including HIV testing and ART uptake, retention, and adherence should be evaluated.",2012-99-08744,22348000,PLoS One,Reuben Granich,2012,7 /,e30216,No,22348000,"Reuben Granich; James G Kahn; Rod Bennett; Charles B Holmes; Navneet Garg; Celicia Serenata; Miriam Lewis Sabin; Carla Makhlouf-Obermeyer; Christina De Filippo Mack; Phoebe Williams; Louisa Jones; Caoimhe Smyth; Kerry A Kutch; Lo Ying-Ru; Marco Vitoria; Yves Souteyrand; Siobhan Crowley; Eline L Korenromp; Brian G Williams; Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050, PLoS One , ; 7 ():1932-6203; e30216",DALY,South Africa,Not Stated,Pharmaceutical,Expanding antiretroviral treatment (ART) to all CD4 levels + current prevention vs. Expanding antiretroviral treatment (ART) to CD4 count <500 + current prevention,Not Stated,Not Stated,Not Stated,"Female, Male",Full,", 5 yrs",3.00,3.00,-468.07,United States,2010,-555.56
28451,Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050,"Antiretroviral Treatment (ART) significantly reduces HIV transmission. We conducted a cost-effectiveness analysis of the impact of expanded ART in South Africa.We model a best case scenario of 90% annual HIV testing coverage in adults 15-49 years old and four ART eligibility scenarios: CD4 count <200 cells/mm(3) (current practice), CD4 count <350, CD4 count <500, all CD4 levels. 2011-2050 outcomes include deaths, disability adjusted life years (DALYs), HIV infections, cost, and cost per DALY averted. Service and ART costs reflect South African data and international generic prices. ART reduces transmission by 92%. We conducted sensitivity analyses.Expanding ART to CD4 count <350 cells/mm(3) prevents an estimated 265,000 (17%) and 1.3 million (15%) new HIV infections over 5 and 40 years, respectively. Cumulative deaths decline 15%, from 12.5 to 10.6 million; DALYs by 14% from 109 to 93 million over 40 years. Costs drop $504 million over 5 years and $3.9 billion over 40 years with breakeven by 2013. Compared with the current scenario, expanding to <500 prevents an additional 585,000 and 3 million new HIV infections over 5 and 40 years, respectively. Expanding to all CD4 levels decreases HIV infections by 3.3 million (45%) and costs by $10 billion over 40 years, with breakeven by 2023. By 2050, using higher ART and monitoring costs, all CD4 levels saves $0.6 billion versus current; other ART scenarios cost $9-194 per DALY averted. If ART reduces transmission by 99%, savings from all CD4 levels reach $17.5 billion. Sensitivity analyses suggest that poor retention and predominant acute phase transmission reduce DALYs averted by 26% and savings by 7%.Increasing the provision of ART to <350 cells/mm3 may significantly reduce costs while reducing the HIV burden. Feasibility including HIV testing and ART uptake, retention, and adherence should be evaluated.",2012-99-08744,22348000,PLoS One,Reuben Granich,2012,7 /,e30216,No,22348000,"Reuben Granich; James G Kahn; Rod Bennett; Charles B Holmes; Navneet Garg; Celicia Serenata; Miriam Lewis Sabin; Carla Makhlouf-Obermeyer; Christina De Filippo Mack; Phoebe Williams; Louisa Jones; Caoimhe Smyth; Kerry A Kutch; Lo Ying-Ru; Marco Vitoria; Yves Souteyrand; Siobhan Crowley; Eline L Korenromp; Brian G Williams; Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050, PLoS One , ; 7 ():1932-6203; e30216",DALY,South Africa,Not Stated,Pharmaceutical,Expanding antiretroviral treatment (ART) to all CD4 levels + current prevention vs. Standard/Usual Care- Expanding antiretroviral treatment (ART) to CD4 count <200 + current prevention,Not Stated,Not Stated,Not Stated,"Female, Male",Full,", 5 yrs",3.00,3.00,-334.15,United States,2010,-396.61
28452,Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050,"Antiretroviral Treatment (ART) significantly reduces HIV transmission. We conducted a cost-effectiveness analysis of the impact of expanded ART in South Africa.We model a best case scenario of 90% annual HIV testing coverage in adults 15-49 years old and four ART eligibility scenarios: CD4 count <200 cells/mm(3) (current practice), CD4 count <350, CD4 count <500, all CD4 levels. 2011-2050 outcomes include deaths, disability adjusted life years (DALYs), HIV infections, cost, and cost per DALY averted. Service and ART costs reflect South African data and international generic prices. ART reduces transmission by 92%. We conducted sensitivity analyses.Expanding ART to CD4 count <350 cells/mm(3) prevents an estimated 265,000 (17%) and 1.3 million (15%) new HIV infections over 5 and 40 years, respectively. Cumulative deaths decline 15%, from 12.5 to 10.6 million; DALYs by 14% from 109 to 93 million over 40 years. Costs drop $504 million over 5 years and $3.9 billion over 40 years with breakeven by 2013. Compared with the current scenario, expanding to <500 prevents an additional 585,000 and 3 million new HIV infections over 5 and 40 years, respectively. Expanding to all CD4 levels decreases HIV infections by 3.3 million (45%) and costs by $10 billion over 40 years, with breakeven by 2023. By 2050, using higher ART and monitoring costs, all CD4 levels saves $0.6 billion versus current; other ART scenarios cost $9-194 per DALY averted. If ART reduces transmission by 99%, savings from all CD4 levels reach $17.5 billion. Sensitivity analyses suggest that poor retention and predominant acute phase transmission reduce DALYs averted by 26% and savings by 7%.Increasing the provision of ART to <350 cells/mm3 may significantly reduce costs while reducing the HIV burden. Feasibility including HIV testing and ART uptake, retention, and adherence should be evaluated.",2012-99-08744,22348000,PLoS One,Reuben Granich,2012,7 /,e30216,No,22348000,"Reuben Granich; James G Kahn; Rod Bennett; Charles B Holmes; Navneet Garg; Celicia Serenata; Miriam Lewis Sabin; Carla Makhlouf-Obermeyer; Christina De Filippo Mack; Phoebe Williams; Louisa Jones; Caoimhe Smyth; Kerry A Kutch; Lo Ying-Ru; Marco Vitoria; Yves Souteyrand; Siobhan Crowley; Eline L Korenromp; Brian G Williams; Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050, PLoS One , ; 7 ():1932-6203; e30216",DALY,South Africa,Not Stated,Pharmaceutical,Expanding antiretroviral treatment (ART) to CD4 count <350 + enhanced prevention vs. Standard/Usual Care- Expanding antiretroviral treatment (ART) to CD4 count <200 + enhanced prevention,Not Stated,Not Stated,Not Stated,"Female, Male",Full,", 5 yrs",3.00,3.00,-253.74,United States,2010,-301.16
28453,Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050,"Antiretroviral Treatment (ART) significantly reduces HIV transmission. We conducted a cost-effectiveness analysis of the impact of expanded ART in South Africa.We model a best case scenario of 90% annual HIV testing coverage in adults 15-49 years old and four ART eligibility scenarios: CD4 count <200 cells/mm(3) (current practice), CD4 count <350, CD4 count <500, all CD4 levels. 2011-2050 outcomes include deaths, disability adjusted life years (DALYs), HIV infections, cost, and cost per DALY averted. Service and ART costs reflect South African data and international generic prices. ART reduces transmission by 92%. We conducted sensitivity analyses.Expanding ART to CD4 count <350 cells/mm(3) prevents an estimated 265,000 (17%) and 1.3 million (15%) new HIV infections over 5 and 40 years, respectively. Cumulative deaths decline 15%, from 12.5 to 10.6 million; DALYs by 14% from 109 to 93 million over 40 years. Costs drop $504 million over 5 years and $3.9 billion over 40 years with breakeven by 2013. Compared with the current scenario, expanding to <500 prevents an additional 585,000 and 3 million new HIV infections over 5 and 40 years, respectively. Expanding to all CD4 levels decreases HIV infections by 3.3 million (45%) and costs by $10 billion over 40 years, with breakeven by 2023. By 2050, using higher ART and monitoring costs, all CD4 levels saves $0.6 billion versus current; other ART scenarios cost $9-194 per DALY averted. If ART reduces transmission by 99%, savings from all CD4 levels reach $17.5 billion. Sensitivity analyses suggest that poor retention and predominant acute phase transmission reduce DALYs averted by 26% and savings by 7%.Increasing the provision of ART to <350 cells/mm3 may significantly reduce costs while reducing the HIV burden. Feasibility including HIV testing and ART uptake, retention, and adherence should be evaluated.",2012-99-08744,22348000,PLoS One,Reuben Granich,2012,7 /,e30216,No,22348000,"Reuben Granich; James G Kahn; Rod Bennett; Charles B Holmes; Navneet Garg; Celicia Serenata; Miriam Lewis Sabin; Carla Makhlouf-Obermeyer; Christina De Filippo Mack; Phoebe Williams; Louisa Jones; Caoimhe Smyth; Kerry A Kutch; Lo Ying-Ru; Marco Vitoria; Yves Souteyrand; Siobhan Crowley; Eline L Korenromp; Brian G Williams; Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050, PLoS One , ; 7 ():1932-6203; e30216",DALY,South Africa,Not Stated,Pharmaceutical,Expanding antiretroviral treatment (ART) to CD4 count <500 + enhanced prevention vs. Expanding antiretroviral treatment (ART) to CD4 count <350 + enhanced prevention,Not Stated,Not Stated,19 Years,"Female, Male",Full,", 5 yrs",3.00,3.00,-323.63,United States,2010,-384.11
28454,Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050,"Antiretroviral Treatment (ART) significantly reduces HIV transmission. We conducted a cost-effectiveness analysis of the impact of expanded ART in South Africa.We model a best case scenario of 90% annual HIV testing coverage in adults 15-49 years old and four ART eligibility scenarios: CD4 count <200 cells/mm(3) (current practice), CD4 count <350, CD4 count <500, all CD4 levels. 2011-2050 outcomes include deaths, disability adjusted life years (DALYs), HIV infections, cost, and cost per DALY averted. Service and ART costs reflect South African data and international generic prices. ART reduces transmission by 92%. We conducted sensitivity analyses.Expanding ART to CD4 count <350 cells/mm(3) prevents an estimated 265,000 (17%) and 1.3 million (15%) new HIV infections over 5 and 40 years, respectively. Cumulative deaths decline 15%, from 12.5 to 10.6 million; DALYs by 14% from 109 to 93 million over 40 years. Costs drop $504 million over 5 years and $3.9 billion over 40 years with breakeven by 2013. Compared with the current scenario, expanding to <500 prevents an additional 585,000 and 3 million new HIV infections over 5 and 40 years, respectively. Expanding to all CD4 levels decreases HIV infections by 3.3 million (45%) and costs by $10 billion over 40 years, with breakeven by 2023. By 2050, using higher ART and monitoring costs, all CD4 levels saves $0.6 billion versus current; other ART scenarios cost $9-194 per DALY averted. If ART reduces transmission by 99%, savings from all CD4 levels reach $17.5 billion. Sensitivity analyses suggest that poor retention and predominant acute phase transmission reduce DALYs averted by 26% and savings by 7%.Increasing the provision of ART to <350 cells/mm3 may significantly reduce costs while reducing the HIV burden. Feasibility including HIV testing and ART uptake, retention, and adherence should be evaluated.",2012-99-08744,22348000,PLoS One,Reuben Granich,2012,7 /,e30216,No,22348000,"Reuben Granich; James G Kahn; Rod Bennett; Charles B Holmes; Navneet Garg; Celicia Serenata; Miriam Lewis Sabin; Carla Makhlouf-Obermeyer; Christina De Filippo Mack; Phoebe Williams; Louisa Jones; Caoimhe Smyth; Kerry A Kutch; Lo Ying-Ru; Marco Vitoria; Yves Souteyrand; Siobhan Crowley; Eline L Korenromp; Brian G Williams; Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050, PLoS One , ; 7 ():1932-6203; e30216",DALY,South Africa,Not Stated,Pharmaceutical,Expanding antiretroviral treatment (ART) to all CD4 levels + enhanced prevention vs. Expanding antiretroviral treatment (ART) to CD4 count <500 + enhanced prevention,Not Stated,Not Stated,Not Stated,"Female, Male",Full,", 5 yrs",3.00,3.00,-366.25,United States,2010,-434.7
28455,Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050,"Antiretroviral Treatment (ART) significantly reduces HIV transmission. We conducted a cost-effectiveness analysis of the impact of expanded ART in South Africa.We model a best case scenario of 90% annual HIV testing coverage in adults 15-49 years old and four ART eligibility scenarios: CD4 count <200 cells/mm(3) (current practice), CD4 count <350, CD4 count <500, all CD4 levels. 2011-2050 outcomes include deaths, disability adjusted life years (DALYs), HIV infections, cost, and cost per DALY averted. Service and ART costs reflect South African data and international generic prices. ART reduces transmission by 92%. We conducted sensitivity analyses.Expanding ART to CD4 count <350 cells/mm(3) prevents an estimated 265,000 (17%) and 1.3 million (15%) new HIV infections over 5 and 40 years, respectively. Cumulative deaths decline 15%, from 12.5 to 10.6 million; DALYs by 14% from 109 to 93 million over 40 years. Costs drop $504 million over 5 years and $3.9 billion over 40 years with breakeven by 2013. Compared with the current scenario, expanding to <500 prevents an additional 585,000 and 3 million new HIV infections over 5 and 40 years, respectively. Expanding to all CD4 levels decreases HIV infections by 3.3 million (45%) and costs by $10 billion over 40 years, with breakeven by 2023. By 2050, using higher ART and monitoring costs, all CD4 levels saves $0.6 billion versus current; other ART scenarios cost $9-194 per DALY averted. If ART reduces transmission by 99%, savings from all CD4 levels reach $17.5 billion. Sensitivity analyses suggest that poor retention and predominant acute phase transmission reduce DALYs averted by 26% and savings by 7%.Increasing the provision of ART to <350 cells/mm3 may significantly reduce costs while reducing the HIV burden. Feasibility including HIV testing and ART uptake, retention, and adherence should be evaluated.",2012-99-08744,22348000,PLoS One,Reuben Granich,2012,7 /,e30216,No,22348000,"Reuben Granich; James G Kahn; Rod Bennett; Charles B Holmes; Navneet Garg; Celicia Serenata; Miriam Lewis Sabin; Carla Makhlouf-Obermeyer; Christina De Filippo Mack; Phoebe Williams; Louisa Jones; Caoimhe Smyth; Kerry A Kutch; Lo Ying-Ru; Marco Vitoria; Yves Souteyrand; Siobhan Crowley; Eline L Korenromp; Brian G Williams; Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050, PLoS One , ; 7 ():1932-6203; e30216",DALY,South Africa,Not Stated,Pharmaceutical,Expanding antiretroviral treatment (ART) to all CD4 levels + enhanced prevention vs. Standard/Usual Care- Expanding antiretroviral treatment (ART) to CD4 count <200 + enhanced prevention,Not Stated,Not Stated,Not Stated,"Female, Male",Full,", 5 yrs",3.00,3.00,-305.44,United States,2010,-362.52
28456,"Integrated HIV testing, malaria, and diarrhea prevention campaign in Kenya: modeled health impact and cost-effectiveness","Efficiently delivered interventions to reduce HIV, malaria, and diarrhea are essential to accelerating global health efforts. A 2008 community integrated prevention campaign in Western Province, Kenya, reached 47,000 individuals over 7 days, providing HIV testing and counseling, water filters, insecticide-treated bed nets, condoms, and for HIV-infected individuals cotrimoxazole prophylaxis and referral for ongoing care. We modeled the potential cost-effectiveness of a scaled-up integrated prevention campaign.We estimated averted deaths and disability-adjusted life years (DALYs) based on published data on baseline mortality and morbidity and on the protective effect of interventions, including antiretroviral therapy. We incorporate a previously estimated scaled-up campaign cost. We used published costs of medical care to estimate savings from averted illness (for all three diseases) and the added costs of initiating treatment earlier in the course of HIV disease.Per 1000 participants, projected reductions in cases of diarrhea, malaria, and HIV infection avert an estimated 16.3 deaths, 359 DALYs and $85,113 in medical care costs. Earlier care for HIV-infected persons adds an estimated 82 DALYs averted (to a total of 442), at a cost of $37,097 (reducing total averted costs to $48,015). Accounting for the estimated campaign cost of $32,000, the campaign saves an estimated $16,015 per 1000 participants. In multivariate sensitivity analyses, 83% of simulations result in net savings, and 93% in a cost per DALY averted of less than $20.A mass, rapidly implemented campaign for HIV testing, safe water, and malaria control appears economically attractive.",2012-99-08741,22347462,PLoS One,James G Kahn,2012,7 /,e31316,No,22347462,"James G Kahn; Nicholas Muraguri; Brian Harris; Eric Lugada; Thomas Clasen; Mark Grabowsky; Jonathan Mermin; Shahnaaz Shariff; Integrated HIV testing, malaria, and diarrhea prevention campaign in Kenya: modeled health impact and cost-effectiveness, PLoS One , ; 7 ():1932-6203; e31316",DALY,Kenya,Not Stated,"Care Delivery, Diagnostic, Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated HIV testing, malaria, and diarrhea prevention campaign vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,Not Stated,Not Stated,-36.25,United States,2008,-43.57
28457,Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana,"Globally, rotavirus gastroenteritis is the most common identifiable cause of severe diarrhea in children under 5. Recently introduced rotavirus vaccines from Merck & Co. and GlaxoSmithKline have the potential to save hundreds of thousands of lives. Efficacy results in Ghana suggest Merck & Co.'s live oral pentavalent rotavirus vaccine (RotaTeq(?)) prevents 65.0% of severe gastroenteritis due to rotavirus infection in children under 5. The announcement by Merck and GSK to make their rotavirus vaccines available for developing nations at reduced prices provides Ghana with the opportunity to introduce rotavirus vaccines into the national immunization program after investigation of the medical, economic and political implications.We estimated the average costs of treating children with diarrhea in the Ashanti region of Ghana as inpatients and outpatients. Using these results, data from rotavirus surveillance studies, and recent rotavirus vaccine efficacy evaluation, we estimated the cost-effectiveness of introducing RotaTeq in Ghana.Based on our prospective calculations, we estimated an average inpatient and outpatient costs of $233.97 and $17.09, respectively, for treating childhood diarrhea. Using the 2003 birth cohort, RotaTeq introduction could save 1554 lives and avert 93,109 disability-adjusted life-years (DALYs) annually. At a market price of $5 per dose, introducing RotaTeq would have a base-case cost of $62.26 per DALY averted, at a market price of $3.50 per dose, a base-case cost of $39.59 per DALY averted and at market cost of $1 per dose, a base-case cost of $1.81 per DALY averted. All three values are below the 2009 Ghana per capita GDP. Thus, RotaTeq introduction into Ghana will be very cost-effective. Sensitivity analyses suggest these results are robust.RotaTeq vaccination for children under five in Ghana would be a highly cost-effective public health intervention. Ghanaian health officials should seek GAVI funding and evaluate how to maximize RotaTeq access.",2012-99-08701,22321664,Vaccine,Collette Abbott,2012,30 /,2582-7,Yes,22321664,"Collette Abbott; Benjamin Tiede; George Armah; Adel Mahmoud; Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana, Vaccine, ; 30 ():1873-2518; 2582-7",DALY,Ghana,Not Stated,Immunization,Live oral pentavalent reassortant rotavirus vaccine vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,62.26,United States,2009,75.11
28458,The population cost-effectiveness of interventions designed to prevent childhood depression,"Depression in childhood and adolescence is common and often persists into adulthood. This study assessed the population-level cost-effectiveness of a preventive intervention that screens children and adolescents for symptoms of depression in schools and the subsequent provision of a psychological intervention to those showing elevated signs of depression. The target population for screening comprised 11- to 17-year-old children and adolescents in the 2003 Australian population.Economic modeling techniques were used to assess the incremental cost-effectiveness of the intervention compared with no intervention. The perspective was that of the health sector, and outcomes were measured by using disability-adjusted life-years (DALYs). Multivariate probabilistic and univariate sensitivity testing was applied to quantify variations in the model parameters.The modeled psychological intervention had an incremental cost-effectiveness ratio of $5400 per DALY averted, with just 2% of iterations falling above a $50?000 per DALY value-for-money threshold. Results were robust to model assumptions.After school screening, screening and the psychological intervention represent good value-for-money. Such an intervention needs to be seriously considered in any national package of preventive health services. Acceptability issues, particularly to intervention providers, including schools and mental health professionals, need to be considered before wide-scale adoption.",2012-99-08684,22312000,Pediatrics,Cathrine Mihalopoulos,2012,129 /,e723-30,No,22312000,"Cathrine Mihalopoulos; Theo Vos; Jane Pirkis; Rob Carter; The population cost-effectiveness of interventions designed to prevent childhood depression, Pediatrics, ; 129 ():1098-4275; e723-30",DALY,Australia,Not Stated,"Screening, Other",Childhood depression prevention- screens children & adolescents in schools followed by psychological intervention vs. None,Not Stated,18 Years,6 Years,"Female, Male",Full,,3.00,3.00,5400,Australia,2003,4955.11
28459,Cost-effectiveness of various tuberculosis control strategies in Thailand,"To evaluate the cost-effectiveness of different tuberculosis control strategies in Thailand.Different tuberculosis control strategies, which included health-worker, community-member, and family-member directly observed treatment (DOT) and a mobile phone ""contact-reminder"" system, were compared with self-administered treatment (SAT). Cost-effectiveness analysis was undertaken by using a decision tree model. Costs (2005 international dollars [I$]) were calculated on the basis of treatment periods and treatment outcomes. Health outcomes were estimated over the lifetime of smear-positive pulmonary tuberculosis patients in disability-adjusted life years (DALYs) averted on the basis of Thai evidence on the efficacy of the selected strategies.Cost-effectiveness results indicate no preference for any strategy. The uncertainty ranges surrounding the health benefits were wide, including a sizeable probability that SAT could lead to more health gain than DOT strategies. The health gain for family-member DOT was 9400 DALYs (95% uncertainty interval -7200 to 25,000), for community-member DOT was 13,000 DALYs (95% uncertainty interval -21,000 to 37,000), and for health-worker DOT was 7900 DALYs (95% uncertainty interval -50,000 to 43,000). There were cost savings (from less multi-drug resistant tuberculosis treatment) associated with family-member DOT (-I$9 million [95% uncertainty interval -I$12 million to -I$5 million]) because the trial treatment failure rate was significantly lower than that for SAT. The mobile phone reminder system was not cost-effective, because the mortality rate associated with it was much higher than that associated with other treatment strategies.Because of the large uncertainty intervals around health gain for DOT strategies, it remains inconclusive whether DOT strategies are more cost-effective than SAT. It is evident, however, that family-member DOT is a cost-saving intervention.",2012-XX-08540,22265067,Value Health,Pojjana Hunchangsith,2012,15 /,S50-5,Yes,22265067,"Pojjana Hunchangsith; Jan J Barendregt; Theo Vos; Melanie Bertram; Cost-effectiveness of various tuberculosis control strategies in Thailand, Value Health, ; 15 ():1098-3015; S50-5",DALY,Thailand,Not Stated,Care Delivery,Patients drug intake is supervised daily for 6 months by a health worker at a health-care facility. vs. Patients take their daily medication without supervision for 6 months.,HIV-negative tuberculosis patients who were sputum smear-positive,Not Stated,12 Years,"Female, Male",Full,,3.00,3.00,1645.57,United States,2005,2180.7
28460,Cost-effectiveness of various tuberculosis control strategies in Thailand,"To evaluate the cost-effectiveness of different tuberculosis control strategies in Thailand.Different tuberculosis control strategies, which included health-worker, community-member, and family-member directly observed treatment (DOT) and a mobile phone ""contact-reminder"" system, were compared with self-administered treatment (SAT). Cost-effectiveness analysis was undertaken by using a decision tree model. Costs (2005 international dollars [I$]) were calculated on the basis of treatment periods and treatment outcomes. Health outcomes were estimated over the lifetime of smear-positive pulmonary tuberculosis patients in disability-adjusted life years (DALYs) averted on the basis of Thai evidence on the efficacy of the selected strategies.Cost-effectiveness results indicate no preference for any strategy. The uncertainty ranges surrounding the health benefits were wide, including a sizeable probability that SAT could lead to more health gain than DOT strategies. The health gain for family-member DOT was 9400 DALYs (95% uncertainty interval -7200 to 25,000), for community-member DOT was 13,000 DALYs (95% uncertainty interval -21,000 to 37,000), and for health-worker DOT was 7900 DALYs (95% uncertainty interval -50,000 to 43,000). There were cost savings (from less multi-drug resistant tuberculosis treatment) associated with family-member DOT (-I$9 million [95% uncertainty interval -I$12 million to -I$5 million]) because the trial treatment failure rate was significantly lower than that for SAT. The mobile phone reminder system was not cost-effective, because the mortality rate associated with it was much higher than that associated with other treatment strategies.Because of the large uncertainty intervals around health gain for DOT strategies, it remains inconclusive whether DOT strategies are more cost-effective than SAT. It is evident, however, that family-member DOT is a cost-saving intervention.",2012-XX-08540,22265067,Value Health,Pojjana Hunchangsith,2012,15 /,S50-5,Yes,22265067,"Pojjana Hunchangsith; Jan J Barendregt; Theo Vos; Melanie Bertram; Cost-effectiveness of various tuberculosis control strategies in Thailand, Value Health, ; 15 ():1098-3015; S50-5",DALY,Thailand,Not Stated,Care Delivery,Patients drug intake is supervised daily for 6 months by a village health volunteer vs. Patients take their daily medication without supervision for 6 months.,HIV-negative TB patients who were sputum smear-positive,Not Stated,12 Years,"Female, Male",Full,,3.00,3.00,-230.77,United States,2005,-305.81
28461,Cost-effectiveness of various tuberculosis control strategies in Thailand,"To evaluate the cost-effectiveness of different tuberculosis control strategies in Thailand.Different tuberculosis control strategies, which included health-worker, community-member, and family-member directly observed treatment (DOT) and a mobile phone ""contact-reminder"" system, were compared with self-administered treatment (SAT). Cost-effectiveness analysis was undertaken by using a decision tree model. Costs (2005 international dollars [I$]) were calculated on the basis of treatment periods and treatment outcomes. Health outcomes were estimated over the lifetime of smear-positive pulmonary tuberculosis patients in disability-adjusted life years (DALYs) averted on the basis of Thai evidence on the efficacy of the selected strategies.Cost-effectiveness results indicate no preference for any strategy. The uncertainty ranges surrounding the health benefits were wide, including a sizeable probability that SAT could lead to more health gain than DOT strategies. The health gain for family-member DOT was 9400 DALYs (95% uncertainty interval -7200 to 25,000), for community-member DOT was 13,000 DALYs (95% uncertainty interval -21,000 to 37,000), and for health-worker DOT was 7900 DALYs (95% uncertainty interval -50,000 to 43,000). There were cost savings (from less multi-drug resistant tuberculosis treatment) associated with family-member DOT (-I$9 million [95% uncertainty interval -I$12 million to -I$5 million]) because the trial treatment failure rate was significantly lower than that for SAT. The mobile phone reminder system was not cost-effective, because the mortality rate associated with it was much higher than that associated with other treatment strategies.Because of the large uncertainty intervals around health gain for DOT strategies, it remains inconclusive whether DOT strategies are more cost-effective than SAT. It is evident, however, that family-member DOT is a cost-saving intervention.",2012-XX-08540,22265067,Value Health,Pojjana Hunchangsith,2012,15 /,S50-5,Yes,22265067,"Pojjana Hunchangsith; Jan J Barendregt; Theo Vos; Melanie Bertram; Cost-effectiveness of various tuberculosis control strategies in Thailand, Value Health, ; 15 ():1098-3015; S50-5",DALY,Thailand,Not Stated,Care Delivery,Patients drug intake is supervised daily for 6 months by a family member (family-member DOT) at the patients home. vs. Patients take their daily medication without supervision for 6 months.,HIV-negative TB patients who were sputum smear-positive,Not Stated,12 Years,"Female, Male",Full,,3.00,3.00,-957.45,United States,2005,-1268.81
28462,Cost-effectiveness of various tuberculosis control strategies in Thailand,"To evaluate the cost-effectiveness of different tuberculosis control strategies in Thailand.Different tuberculosis control strategies, which included health-worker, community-member, and family-member directly observed treatment (DOT) and a mobile phone ""contact-reminder"" system, were compared with self-administered treatment (SAT). Cost-effectiveness analysis was undertaken by using a decision tree model. Costs (2005 international dollars [I$]) were calculated on the basis of treatment periods and treatment outcomes. Health outcomes were estimated over the lifetime of smear-positive pulmonary tuberculosis patients in disability-adjusted life years (DALYs) averted on the basis of Thai evidence on the efficacy of the selected strategies.Cost-effectiveness results indicate no preference for any strategy. The uncertainty ranges surrounding the health benefits were wide, including a sizeable probability that SAT could lead to more health gain than DOT strategies. The health gain for family-member DOT was 9400 DALYs (95% uncertainty interval -7200 to 25,000), for community-member DOT was 13,000 DALYs (95% uncertainty interval -21,000 to 37,000), and for health-worker DOT was 7900 DALYs (95% uncertainty interval -50,000 to 43,000). There were cost savings (from less multi-drug resistant tuberculosis treatment) associated with family-member DOT (-I$9 million [95% uncertainty interval -I$12 million to -I$5 million]) because the trial treatment failure rate was significantly lower than that for SAT. The mobile phone reminder system was not cost-effective, because the mortality rate associated with it was much higher than that associated with other treatment strategies.Because of the large uncertainty intervals around health gain for DOT strategies, it remains inconclusive whether DOT strategies are more cost-effective than SAT. It is evident, however, that family-member DOT is a cost-saving intervention.",2012-XX-08540,22265067,Value Health,Pojjana Hunchangsith,2012,15 /,S50-5,Yes,22265067,"Pojjana Hunchangsith; Jan J Barendregt; Theo Vos; Melanie Bertram; Cost-effectiveness of various tuberculosis control strategies in Thailand, Value Health, ; 15 ():1098-3015; S50-5",DALY,Thailand,Not Stated,Care Delivery,Mobile phone contact-reminder to take daily medication by village health volunteers vs. Patients take their daily medication without supervision for 6 months.,HIV-negative tuberculosis patients who were sputum smear-positive,Not Stated,12 Years,"Female, Male",Full,,3.00,3.00,350,United States,2005,463.82
28463,Cost-effectiveness analysis for antidepressants and cognitive behavioral therapy for major depression in Thailand,"To determine the cost-effectiveness of fluoxetine and cognitive-behavioral therapy (CBT) for major depression in Thailand.A microsimulation model was developed to describe the variation in course of disease between individuals. Model inputs included Thai data on disease parameters and costs while impact measures were derived from a systematic review and meta-analysis of the international literature. Fluoxetine as the cheapest antidepressant drug in Thailand was analyzed for treatment of episodes plus a 6-month continuation phase and for maintenance treatment over 5 years of follow-up. CBT was analyzed for episodic treatment and for 5-year maintenance treatment. Results are presented as cost (Thai bahts) per disability-adjusted life-year (DALY) averted, compared with a ""do-nothing"" scenario.The cost-effectiveness ratios of all interventions were below 1 time Thailand's gross domestic product of 110,000 bahts per capita. The uncertainty ranges around the cost-effectiveness ratios overlap: maintenance treatment with CBT 11,000 bahts per DALY (8,000-14,000); episodic treatment with CBT 23,000 bahts per DALY (10,000-36,000); episodic plus continuation drug treatment 33,000 bahts per DALY (26,000-44,000); maintenance drug treatment 38,000 bahts per DALY (30,000-48,000); and episodic drug treatment 42,000 bahts per DALY (32,000-57,000).CBT and generic fluoxetine are cost-effective treatment options for both episodic and maintenance treatment of major depression in Thailand. Maintenance treatment has the greatest potential of health gain.",2012-XX-08539,22265064,Value Health,Benjamas Prukkanone,2012,15 /,S3-8,Yes,22265064,"Benjamas Prukkanone; Theo Vos; Melanie Bertram; Stephen Lim; Cost-effectiveness analysis for antidepressants and cognitive behavioral therapy for major depression in Thailand, Value Health, ; 15 ():1098-3015; S3-8",DALY,Thailand,Not Stated,"Health Education or Behavior, Pharmaceutical",Episodic drug treatment for major depression vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,42000,Thailand,2005,1383.85
28464,Cost-effectiveness analysis for antidepressants and cognitive behavioral therapy for major depression in Thailand,"To determine the cost-effectiveness of fluoxetine and cognitive-behavioral therapy (CBT) for major depression in Thailand.A microsimulation model was developed to describe the variation in course of disease between individuals. Model inputs included Thai data on disease parameters and costs while impact measures were derived from a systematic review and meta-analysis of the international literature. Fluoxetine as the cheapest antidepressant drug in Thailand was analyzed for treatment of episodes plus a 6-month continuation phase and for maintenance treatment over 5 years of follow-up. CBT was analyzed for episodic treatment and for 5-year maintenance treatment. Results are presented as cost (Thai bahts) per disability-adjusted life-year (DALY) averted, compared with a ""do-nothing"" scenario.The cost-effectiveness ratios of all interventions were below 1 time Thailand's gross domestic product of 110,000 bahts per capita. The uncertainty ranges around the cost-effectiveness ratios overlap: maintenance treatment with CBT 11,000 bahts per DALY (8,000-14,000); episodic treatment with CBT 23,000 bahts per DALY (10,000-36,000); episodic plus continuation drug treatment 33,000 bahts per DALY (26,000-44,000); maintenance drug treatment 38,000 bahts per DALY (30,000-48,000); and episodic drug treatment 42,000 bahts per DALY (32,000-57,000).CBT and generic fluoxetine are cost-effective treatment options for both episodic and maintenance treatment of major depression in Thailand. Maintenance treatment has the greatest potential of health gain.",2012-XX-08539,22265064,Value Health,Benjamas Prukkanone,2012,15 /,S3-8,Yes,22265064,"Benjamas Prukkanone; Theo Vos; Melanie Bertram; Stephen Lim; Cost-effectiveness analysis for antidepressants and cognitive behavioral therapy for major depression in Thailand, Value Health, ; 15 ():1098-3015; S3-8",DALY,Thailand,Not Stated,"Health Education or Behavior, Pharmaceutical",Continuation drug treatment vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,33000,Thailand,2005,1087.31
28465,Cost-effectiveness analysis for antidepressants and cognitive behavioral therapy for major depression in Thailand,"To determine the cost-effectiveness of fluoxetine and cognitive-behavioral therapy (CBT) for major depression in Thailand.A microsimulation model was developed to describe the variation in course of disease between individuals. Model inputs included Thai data on disease parameters and costs while impact measures were derived from a systematic review and meta-analysis of the international literature. Fluoxetine as the cheapest antidepressant drug in Thailand was analyzed for treatment of episodes plus a 6-month continuation phase and for maintenance treatment over 5 years of follow-up. CBT was analyzed for episodic treatment and for 5-year maintenance treatment. Results are presented as cost (Thai bahts) per disability-adjusted life-year (DALY) averted, compared with a ""do-nothing"" scenario.The cost-effectiveness ratios of all interventions were below 1 time Thailand's gross domestic product of 110,000 bahts per capita. The uncertainty ranges around the cost-effectiveness ratios overlap: maintenance treatment with CBT 11,000 bahts per DALY (8,000-14,000); episodic treatment with CBT 23,000 bahts per DALY (10,000-36,000); episodic plus continuation drug treatment 33,000 bahts per DALY (26,000-44,000); maintenance drug treatment 38,000 bahts per DALY (30,000-48,000); and episodic drug treatment 42,000 bahts per DALY (32,000-57,000).CBT and generic fluoxetine are cost-effective treatment options for both episodic and maintenance treatment of major depression in Thailand. Maintenance treatment has the greatest potential of health gain.",2012-XX-08539,22265064,Value Health,Benjamas Prukkanone,2012,15 /,S3-8,Yes,22265064,"Benjamas Prukkanone; Theo Vos; Melanie Bertram; Stephen Lim; Cost-effectiveness analysis for antidepressants and cognitive behavioral therapy for major depression in Thailand, Value Health, ; 15 ():1098-3015; S3-8",DALY,Thailand,Not Stated,"Health Education or Behavior, Pharmaceutical",Maintenance drug treatment for major depression vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,38000,Thailand,2005,1252.06
28466,Cost-effectiveness analysis for antidepressants and cognitive behavioral therapy for major depression in Thailand,"To determine the cost-effectiveness of fluoxetine and cognitive-behavioral therapy (CBT) for major depression in Thailand.A microsimulation model was developed to describe the variation in course of disease between individuals. Model inputs included Thai data on disease parameters and costs while impact measures were derived from a systematic review and meta-analysis of the international literature. Fluoxetine as the cheapest antidepressant drug in Thailand was analyzed for treatment of episodes plus a 6-month continuation phase and for maintenance treatment over 5 years of follow-up. CBT was analyzed for episodic treatment and for 5-year maintenance treatment. Results are presented as cost (Thai bahts) per disability-adjusted life-year (DALY) averted, compared with a ""do-nothing"" scenario.The cost-effectiveness ratios of all interventions were below 1 time Thailand's gross domestic product of 110,000 bahts per capita. The uncertainty ranges around the cost-effectiveness ratios overlap: maintenance treatment with CBT 11,000 bahts per DALY (8,000-14,000); episodic treatment with CBT 23,000 bahts per DALY (10,000-36,000); episodic plus continuation drug treatment 33,000 bahts per DALY (26,000-44,000); maintenance drug treatment 38,000 bahts per DALY (30,000-48,000); and episodic drug treatment 42,000 bahts per DALY (32,000-57,000).CBT and generic fluoxetine are cost-effective treatment options for both episodic and maintenance treatment of major depression in Thailand. Maintenance treatment has the greatest potential of health gain.",2012-XX-08539,22265064,Value Health,Benjamas Prukkanone,2012,15 /,S3-8,Yes,22265064,"Benjamas Prukkanone; Theo Vos; Melanie Bertram; Stephen Lim; Cost-effectiveness analysis for antidepressants and cognitive behavioral therapy for major depression in Thailand, Value Health, ; 15 ():1098-3015; S3-8",DALY,Thailand,Not Stated,"Health Education or Behavior, Pharmaceutical",Episodal cognitive behavioral therapy in the treatment of depression alone or combined with drug therapy. vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,23000,Thailand,2005,757.82
28467,Cost-effectiveness analysis for antidepressants and cognitive behavioral therapy for major depression in Thailand,"To determine the cost-effectiveness of fluoxetine and cognitive-behavioral therapy (CBT) for major depression in Thailand.A microsimulation model was developed to describe the variation in course of disease between individuals. Model inputs included Thai data on disease parameters and costs while impact measures were derived from a systematic review and meta-analysis of the international literature. Fluoxetine as the cheapest antidepressant drug in Thailand was analyzed for treatment of episodes plus a 6-month continuation phase and for maintenance treatment over 5 years of follow-up. CBT was analyzed for episodic treatment and for 5-year maintenance treatment. Results are presented as cost (Thai bahts) per disability-adjusted life-year (DALY) averted, compared with a ""do-nothing"" scenario.The cost-effectiveness ratios of all interventions were below 1 time Thailand's gross domestic product of 110,000 bahts per capita. The uncertainty ranges around the cost-effectiveness ratios overlap: maintenance treatment with CBT 11,000 bahts per DALY (8,000-14,000); episodic treatment with CBT 23,000 bahts per DALY (10,000-36,000); episodic plus continuation drug treatment 33,000 bahts per DALY (26,000-44,000); maintenance drug treatment 38,000 bahts per DALY (30,000-48,000); and episodic drug treatment 42,000 bahts per DALY (32,000-57,000).CBT and generic fluoxetine are cost-effective treatment options for both episodic and maintenance treatment of major depression in Thailand. Maintenance treatment has the greatest potential of health gain.",2012-XX-08539,22265064,Value Health,Benjamas Prukkanone,2012,15 /,S3-8,Yes,22265064,"Benjamas Prukkanone; Theo Vos; Melanie Bertram; Stephen Lim; Cost-effectiveness analysis for antidepressants and cognitive behavioral therapy for major depression in Thailand, Value Health, ; 15 ():1098-3015; S3-8",DALY,Thailand,Not Stated,"Health Education or Behavior, Pharmaceutical",Maintenance cognitive behavioral therapy:CBT is a nonpharmacological intervention that is effective in the treatment of depression alone or combined with drug therapy. vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,11000,Thailand,2005,362.44
28468,Potential impact and cost-effectiveness of multi-biofortified rice in China,"Biofortification, that is, improving the micronutrient content of staple foods through crop breeding, could be a pro-poor, pro-rural, agriculture-based intervention to reduce the health burden of micronutrient malnutrition. While the potential cost-effectiveness of crops biofortified with single micronutrients was shown in previous research, poor people often suffer from multiple micronutrient deficiencies, which should be accounted for in biofortification initiatives. This study is the first to estimate the potential health benefits and cost-effectiveness of multi-biofortification. Rice with enhanced provitamin A, zinc, iron and folate concentrations is used as a concrete example. The research is conducted for China, the largest rice producer in the world, where micronutrient malnutrition remains a major public health problem. Using the DALY (disability-adjusted life year) framework, the current annual health burden of the four micronutrient deficiencies in China is estimated at 10.6 million DALYs. Introducing multi-biofortified rice could lower this burden by up to 46%. Given the large positive health impact and low recurrent costs of multi-biofortification, this intervention could be very cost effective: under optimistic assumptions, the cost per DALY saved would be around US$ 2; it would stay below US$ 10 even under pessimistic assumptions.",2012-XX-08399,22154941,N Biotechnol,Hans De Steur,2012,29 /,432-42,No,22154941,"Hans De Steur; Xavier Gellynck; Dieter Blancquaert; Willy Lambert; Dominique Van Der Straeten; Matin Qaim; Potential impact and cost-effectiveness of multi-biofortified rice in China, N Biotechnol , ; 29 ():1876-4347; 432-42",DALY,China,Not Stated,Other,Folate biofortified rice vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,21.4,United States,2010,25.4
28469,Potential impact and cost-effectiveness of multi-biofortified rice in China,"Biofortification, that is, improving the micronutrient content of staple foods through crop breeding, could be a pro-poor, pro-rural, agriculture-based intervention to reduce the health burden of micronutrient malnutrition. While the potential cost-effectiveness of crops biofortified with single micronutrients was shown in previous research, poor people often suffer from multiple micronutrient deficiencies, which should be accounted for in biofortification initiatives. This study is the first to estimate the potential health benefits and cost-effectiveness of multi-biofortification. Rice with enhanced provitamin A, zinc, iron and folate concentrations is used as a concrete example. The research is conducted for China, the largest rice producer in the world, where micronutrient malnutrition remains a major public health problem. Using the DALY (disability-adjusted life year) framework, the current annual health burden of the four micronutrient deficiencies in China is estimated at 10.6 million DALYs. Introducing multi-biofortified rice could lower this burden by up to 46%. Given the large positive health impact and low recurrent costs of multi-biofortification, this intervention could be very cost effective: under optimistic assumptions, the cost per DALY saved would be around US$ 2; it would stay below US$ 10 even under pessimistic assumptions.",2012-XX-08399,22154941,N Biotechnol,Hans De Steur,2012,29 /,432-42,No,22154941,"Hans De Steur; Xavier Gellynck; Dieter Blancquaert; Willy Lambert; Dominique Van Der Straeten; Matin Qaim; Potential impact and cost-effectiveness of multi-biofortified rice in China, N Biotechnol , ; 29 ():1876-4347; 432-42",DALY,China,Not Stated,Other,Provitamin A biofortified rice vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,5,United States,2010,5.93
28470,Potential impact and cost-effectiveness of multi-biofortified rice in China,"Biofortification, that is, improving the micronutrient content of staple foods through crop breeding, could be a pro-poor, pro-rural, agriculture-based intervention to reduce the health burden of micronutrient malnutrition. While the potential cost-effectiveness of crops biofortified with single micronutrients was shown in previous research, poor people often suffer from multiple micronutrient deficiencies, which should be accounted for in biofortification initiatives. This study is the first to estimate the potential health benefits and cost-effectiveness of multi-biofortification. Rice with enhanced provitamin A, zinc, iron and folate concentrations is used as a concrete example. The research is conducted for China, the largest rice producer in the world, where micronutrient malnutrition remains a major public health problem. Using the DALY (disability-adjusted life year) framework, the current annual health burden of the four micronutrient deficiencies in China is estimated at 10.6 million DALYs. Introducing multi-biofortified rice could lower this burden by up to 46%. Given the large positive health impact and low recurrent costs of multi-biofortification, this intervention could be very cost effective: under optimistic assumptions, the cost per DALY saved would be around US$ 2; it would stay below US$ 10 even under pessimistic assumptions.",2012-XX-08399,22154941,N Biotechnol,Hans De Steur,2012,29 /,432-42,No,22154941,"Hans De Steur; Xavier Gellynck; Dieter Blancquaert; Willy Lambert; Dominique Van Der Straeten; Matin Qaim; Potential impact and cost-effectiveness of multi-biofortified rice in China, N Biotechnol , ; 29 ():1876-4347; 432-42",DALY,China,Not Stated,Other,Zinc biofortified rice vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,1.2,United States,2010,1.42
28471,Potential impact and cost-effectiveness of multi-biofortified rice in China,"Biofortification, that is, improving the micronutrient content of staple foods through crop breeding, could be a pro-poor, pro-rural, agriculture-based intervention to reduce the health burden of micronutrient malnutrition. While the potential cost-effectiveness of crops biofortified with single micronutrients was shown in previous research, poor people often suffer from multiple micronutrient deficiencies, which should be accounted for in biofortification initiatives. This study is the first to estimate the potential health benefits and cost-effectiveness of multi-biofortification. Rice with enhanced provitamin A, zinc, iron and folate concentrations is used as a concrete example. The research is conducted for China, the largest rice producer in the world, where micronutrient malnutrition remains a major public health problem. Using the DALY (disability-adjusted life year) framework, the current annual health burden of the four micronutrient deficiencies in China is estimated at 10.6 million DALYs. Introducing multi-biofortified rice could lower this burden by up to 46%. Given the large positive health impact and low recurrent costs of multi-biofortification, this intervention could be very cost effective: under optimistic assumptions, the cost per DALY saved would be around US$ 2; it would stay below US$ 10 even under pessimistic assumptions.",2012-XX-08399,22154941,N Biotechnol,Hans De Steur,2012,29 /,432-42,No,22154941,"Hans De Steur; Xavier Gellynck; Dieter Blancquaert; Willy Lambert; Dominique Van Der Straeten; Matin Qaim; Potential impact and cost-effectiveness of multi-biofortified rice in China, N Biotechnol , ; 29 ():1876-4347; 432-42",DALY,China,Not Stated,Other,Iron biofortified rice vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,0.8,United States,2010,0.95
28472,Potential impact and cost-effectiveness of multi-biofortified rice in China,"Biofortification, that is, improving the micronutrient content of staple foods through crop breeding, could be a pro-poor, pro-rural, agriculture-based intervention to reduce the health burden of micronutrient malnutrition. While the potential cost-effectiveness of crops biofortified with single micronutrients was shown in previous research, poor people often suffer from multiple micronutrient deficiencies, which should be accounted for in biofortification initiatives. This study is the first to estimate the potential health benefits and cost-effectiveness of multi-biofortification. Rice with enhanced provitamin A, zinc, iron and folate concentrations is used as a concrete example. The research is conducted for China, the largest rice producer in the world, where micronutrient malnutrition remains a major public health problem. Using the DALY (disability-adjusted life year) framework, the current annual health burden of the four micronutrient deficiencies in China is estimated at 10.6 million DALYs. Introducing multi-biofortified rice could lower this burden by up to 46%. Given the large positive health impact and low recurrent costs of multi-biofortification, this intervention could be very cost effective: under optimistic assumptions, the cost per DALY saved would be around US$ 2; it would stay below US$ 10 even under pessimistic assumptions.",2012-XX-08399,22154941,N Biotechnol,Hans De Steur,2012,29 /,432-42,No,22154941,"Hans De Steur; Xavier Gellynck; Dieter Blancquaert; Willy Lambert; Dominique Van Der Straeten; Matin Qaim; Potential impact and cost-effectiveness of multi-biofortified rice in China, N Biotechnol , ; 29 ():1876-4347; 432-42",DALY,China,Not Stated,Other,Multi-biofortified rice vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,2.3,United States,2010,2.73
28473,Would vaccination against nicotine be a cost-effective way to prevent smoking uptake in adolescents?,"Aims We used epidemiological modelling to assess whether nicotine vaccines would be a cost-effective way of preventing smoking uptake in adolescents. Design, Setting, Participants and Measurements We built an epidemiological model using Australian data on age-specific smoking prevalence; smoking cessation and relapse rates; life-time sex-specific disability-adjusted life years lived for cohorts of 100 000 smokers and non-smokers; government data on the costs of delivering a vaccination programme by general practitioners; and a range of plausible and optimistic estimates of vaccine cost, efficacy and immune response rates based on clinical trial results. We first estimated the smoking uptake rates for Australians aged 12-19 years. We then used these estimates to predict the expected smoking prevalence in a birth cohort aged 12 in 2003 by age 20 under (i) current policy and (ii) different vaccination scenarios that varied in cost, initial vaccination uptake, yearly re-vaccination rates, efficacy and a favourable vaccine immune response rate. Findings Under the most optimistic assumptions, the cost to avert a smoker at age 20 was $44 431 [95% confidence interval (CI) $40 023-49 250]. This increased to $296 019 (95% CI $252 307-$355 930) under more plausible scenarios. The vaccine programme was not cost-effective under any scenario. Conclusions A preventive nicotine vaccination programme is unlikely to be cost-effective. The total cost of a universal vaccination programme would be high and its impact on population smoking prevalence negligible. For these reasons, such a programme is unlikely to be publicly funded in Australia or any other developed country.",2012-99-08295,22084967,Addiction,Coral E Gartner,2011,/,,No,22084967,"Coral E Gartner; Jan J Barendregt; Angela Wallace; Wayne D Hall; Would vaccination against nicotine be a cost-effective way to prevent smoking uptake in adolescents?, Addiction, ; ():0965-2140",DALY,Australia,Not Stated,Immunization,Nicotine vaccination program vs. Standard/Usual Care,Not Stated,40 Years,12 Years,"Female, Male",Full,,Not Stated,3.00,215872,Australia,2009,206426.93
28474,Modelling the impact on avoidable cardiovascular disease burden and costs of interventions to lower SBP in the England population,"The burden of disease from cardiovascular disease (CVD) remains significant in England. Blood pressure remains an important risk factor. Health gain through public health measures and improving treatment compliance are potentially likely to be high. We assess the impact of known cost-effective interventions in terms of the avoidable CVD burden and costs by comparing these strategies to the current situation.We modelled avoidable CVD outcomes simulating the English population aged over 16 years with Excel spreadsheets for the current prevention/treatment and following various interventions over a 10-year time frame. The outcome measures were avoidable incident heart disease and stroke events, deaths and disability-adjusted life years (DALYs). Costs are reported from the health service perspective. We analysed relative cost-effectiveness, undertook sensitivity analysis and measured relative impacts of different strategies on avoidable burden of disease.The assessed interventions have a potential to reduce the current burden of disease between 70?000 and about 1?million DALYs over the 10-year frame. Although all interventions were cost-effective, some (e.g. Salt reduction in the population and 'Dietary Approaches to Stop Hypertension-sodium', which modelled the impact of salt reduction and dietary approaches) were cost-saving. The cost-effectiveness of treatment strategies was sensitive to drug costs.Evidence-based interventions appropriately scaled up for both prevention and treatment of blood pressure lead to important additional potential health gains. There was noticeable variance in cost-effectiveness and impact among the different interventions at a population level. Taking into account impact, priority should be given to prevention to reduce blood pressure at a population level through reduced salt consumption.",2011-99-08289,22080224,J Hypertens,Hiten Dodhia,2012,30 /,217-26,No,22080224,"Hiten Dodhia; Karen Phillips; Maria-Irini Zannou; Mara Airoldi; Gwyn Bevan; Modelling the impact on avoidable cardiovascular disease burden and costs of interventions to lower SBP in the England population, J Hypertens, ; 30 ():0263-6352; 217-26",DALY,United Kingdom,Not Stated,"Health Education or Behavior, Pharmaceutical","First-line antihypertensive drug with blood pressure >40/90 mmHg; improved levels of detection, treatment and control of people with high blood pressure with poor control vs. Standard/Usual Care",Not Stated,Not Stated,41 Years,"Female, Male",Full,,3.50,3.50,5906,United Kingdom,2006,13976.47
28475,Modelling the impact on avoidable cardiovascular disease burden and costs of interventions to lower SBP in the England population,"The burden of disease from cardiovascular disease (CVD) remains significant in England. Blood pressure remains an important risk factor. Health gain through public health measures and improving treatment compliance are potentially likely to be high. We assess the impact of known cost-effective interventions in terms of the avoidable CVD burden and costs by comparing these strategies to the current situation.We modelled avoidable CVD outcomes simulating the English population aged over 16 years with Excel spreadsheets for the current prevention/treatment and following various interventions over a 10-year time frame. The outcome measures were avoidable incident heart disease and stroke events, deaths and disability-adjusted life years (DALYs). Costs are reported from the health service perspective. We analysed relative cost-effectiveness, undertook sensitivity analysis and measured relative impacts of different strategies on avoidable burden of disease.The assessed interventions have a potential to reduce the current burden of disease between 70?000 and about 1?million DALYs over the 10-year frame. Although all interventions were cost-effective, some (e.g. Salt reduction in the population and 'Dietary Approaches to Stop Hypertension-sodium', which modelled the impact of salt reduction and dietary approaches) were cost-saving. The cost-effectiveness of treatment strategies was sensitive to drug costs.Evidence-based interventions appropriately scaled up for both prevention and treatment of blood pressure lead to important additional potential health gains. There was noticeable variance in cost-effectiveness and impact among the different interventions at a population level. Taking into account impact, priority should be given to prevention to reduce blood pressure at a population level through reduced salt consumption.",2011-99-08289,22080224,J Hypertens,Hiten Dodhia,2012,30 /,217-26,No,22080224,"Hiten Dodhia; Karen Phillips; Maria-Irini Zannou; Mara Airoldi; Gwyn Bevan; Modelling the impact on avoidable cardiovascular disease burden and costs of interventions to lower SBP in the England population, J Hypertens, ; 30 ():0263-6352; 217-26",DALY,United Kingdom,Not Stated,"Health Education or Behavior, Pharmaceutical",First-line antihypertensive drug with blood pressure >40/90 mmHg; 100% detection but current levels of treatment and control of people with high blood pressure with poor control vs. Standard/Usual Care,Not Stated,Not Stated,41 Years,"Female, Male",Full,,3.50,3.50,12545,United Kingdom,2006,29687.58
28476,Modelling the impact on avoidable cardiovascular disease burden and costs of interventions to lower SBP in the England population,"The burden of disease from cardiovascular disease (CVD) remains significant in England. Blood pressure remains an important risk factor. Health gain through public health measures and improving treatment compliance are potentially likely to be high. We assess the impact of known cost-effective interventions in terms of the avoidable CVD burden and costs by comparing these strategies to the current situation.We modelled avoidable CVD outcomes simulating the English population aged over 16 years with Excel spreadsheets for the current prevention/treatment and following various interventions over a 10-year time frame. The outcome measures were avoidable incident heart disease and stroke events, deaths and disability-adjusted life years (DALYs). Costs are reported from the health service perspective. We analysed relative cost-effectiveness, undertook sensitivity analysis and measured relative impacts of different strategies on avoidable burden of disease.The assessed interventions have a potential to reduce the current burden of disease between 70?000 and about 1?million DALYs over the 10-year frame. Although all interventions were cost-effective, some (e.g. Salt reduction in the population and 'Dietary Approaches to Stop Hypertension-sodium', which modelled the impact of salt reduction and dietary approaches) were cost-saving. The cost-effectiveness of treatment strategies was sensitive to drug costs.Evidence-based interventions appropriately scaled up for both prevention and treatment of blood pressure lead to important additional potential health gains. There was noticeable variance in cost-effectiveness and impact among the different interventions at a population level. Taking into account impact, priority should be given to prevention to reduce blood pressure at a population level through reduced salt consumption.",2011-99-08289,22080224,J Hypertens,Hiten Dodhia,2012,30 /,217-26,No,22080224,"Hiten Dodhia; Karen Phillips; Maria-Irini Zannou; Mara Airoldi; Gwyn Bevan; Modelling the impact on avoidable cardiovascular disease burden and costs of interventions to lower SBP in the England population, J Hypertens, ; 30 ():0263-6352; 217-26",DALY,United Kingdom,Not Stated,"Health Education or Behavior, Pharmaceutical",Treatment with first line antihypertensive therapy vs. Standard/Usual Care,Not Stated,Not Stated,41 Years,"Female, Male",Full,,3.50,3.50,1006,United Kingdom,2006,2380.69
28477,Modelling the impact on avoidable cardiovascular disease burden and costs of interventions to lower SBP in the England population,"The burden of disease from cardiovascular disease (CVD) remains significant in England. Blood pressure remains an important risk factor. Health gain through public health measures and improving treatment compliance are potentially likely to be high. We assess the impact of known cost-effective interventions in terms of the avoidable CVD burden and costs by comparing these strategies to the current situation.We modelled avoidable CVD outcomes simulating the English population aged over 16 years with Excel spreadsheets for the current prevention/treatment and following various interventions over a 10-year time frame. The outcome measures were avoidable incident heart disease and stroke events, deaths and disability-adjusted life years (DALYs). Costs are reported from the health service perspective. We analysed relative cost-effectiveness, undertook sensitivity analysis and measured relative impacts of different strategies on avoidable burden of disease.The assessed interventions have a potential to reduce the current burden of disease between 70?000 and about 1?million DALYs over the 10-year frame. Although all interventions were cost-effective, some (e.g. Salt reduction in the population and 'Dietary Approaches to Stop Hypertension-sodium', which modelled the impact of salt reduction and dietary approaches) were cost-saving. The cost-effectiveness of treatment strategies was sensitive to drug costs.Evidence-based interventions appropriately scaled up for both prevention and treatment of blood pressure lead to important additional potential health gains. There was noticeable variance in cost-effectiveness and impact among the different interventions at a population level. Taking into account impact, priority should be given to prevention to reduce blood pressure at a population level through reduced salt consumption.",2011-99-08289,22080224,J Hypertens,Hiten Dodhia,2012,30 /,217-26,No,22080224,"Hiten Dodhia; Karen Phillips; Maria-Irini Zannou; Mara Airoldi; Gwyn Bevan; Modelling the impact on avoidable cardiovascular disease burden and costs of interventions to lower SBP in the England population, J Hypertens, ; 30 ():0263-6352; 217-26",DALY,United Kingdom,Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Reduce average blood pressure by reducing salt content vs. Standard/Usual Care,Not Stated,Not Stated,41 Years,"Female, Male",Full,,3.50,3.50,Not Stated,United Kingdom,2006,Not Stated
28478,Modelling the impact on avoidable cardiovascular disease burden and costs of interventions to lower SBP in the England population,"The burden of disease from cardiovascular disease (CVD) remains significant in England. Blood pressure remains an important risk factor. Health gain through public health measures and improving treatment compliance are potentially likely to be high. We assess the impact of known cost-effective interventions in terms of the avoidable CVD burden and costs by comparing these strategies to the current situation.We modelled avoidable CVD outcomes simulating the English population aged over 16 years with Excel spreadsheets for the current prevention/treatment and following various interventions over a 10-year time frame. The outcome measures were avoidable incident heart disease and stroke events, deaths and disability-adjusted life years (DALYs). Costs are reported from the health service perspective. We analysed relative cost-effectiveness, undertook sensitivity analysis and measured relative impacts of different strategies on avoidable burden of disease.The assessed interventions have a potential to reduce the current burden of disease between 70?000 and about 1?million DALYs over the 10-year frame. Although all interventions were cost-effective, some (e.g. Salt reduction in the population and 'Dietary Approaches to Stop Hypertension-sodium', which modelled the impact of salt reduction and dietary approaches) were cost-saving. The cost-effectiveness of treatment strategies was sensitive to drug costs.Evidence-based interventions appropriately scaled up for both prevention and treatment of blood pressure lead to important additional potential health gains. There was noticeable variance in cost-effectiveness and impact among the different interventions at a population level. Taking into account impact, priority should be given to prevention to reduce blood pressure at a population level through reduced salt consumption.",2011-99-08289,22080224,J Hypertens,Hiten Dodhia,2012,30 /,217-26,No,22080224,"Hiten Dodhia; Karen Phillips; Maria-Irini Zannou; Mara Airoldi; Gwyn Bevan; Modelling the impact on avoidable cardiovascular disease burden and costs of interventions to lower SBP in the England population, J Hypertens, ; 30 ():0263-6352; 217-26",DALY,United Kingdom,Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Targeted dietary advice & average 5 mmHg reduction in systolic blood pressure (SBP) vs. Standard/Usual Care,Not Stated,Not Stated,41 Years,"Female, Male",Full,,3.50,3.50,Not Stated,United Kingdom,2006,Not Stated
28479,Modelling the impact on avoidable cardiovascular disease burden and costs of interventions to lower SBP in the England population,"The burden of disease from cardiovascular disease (CVD) remains significant in England. Blood pressure remains an important risk factor. Health gain through public health measures and improving treatment compliance are potentially likely to be high. We assess the impact of known cost-effective interventions in terms of the avoidable CVD burden and costs by comparing these strategies to the current situation.We modelled avoidable CVD outcomes simulating the English population aged over 16 years with Excel spreadsheets for the current prevention/treatment and following various interventions over a 10-year time frame. The outcome measures were avoidable incident heart disease and stroke events, deaths and disability-adjusted life years (DALYs). Costs are reported from the health service perspective. We analysed relative cost-effectiveness, undertook sensitivity analysis and measured relative impacts of different strategies on avoidable burden of disease.The assessed interventions have a potential to reduce the current burden of disease between 70?000 and about 1?million DALYs over the 10-year frame. Although all interventions were cost-effective, some (e.g. Salt reduction in the population and 'Dietary Approaches to Stop Hypertension-sodium', which modelled the impact of salt reduction and dietary approaches) were cost-saving. The cost-effectiveness of treatment strategies was sensitive to drug costs.Evidence-based interventions appropriately scaled up for both prevention and treatment of blood pressure lead to important additional potential health gains. There was noticeable variance in cost-effectiveness and impact among the different interventions at a population level. Taking into account impact, priority should be given to prevention to reduce blood pressure at a population level through reduced salt consumption.",2011-99-08289,22080224,J Hypertens,Hiten Dodhia,2012,30 /,217-26,No,22080224,"Hiten Dodhia; Karen Phillips; Maria-Irini Zannou; Mara Airoldi; Gwyn Bevan; Modelling the impact on avoidable cardiovascular disease burden and costs of interventions to lower SBP in the England population, J Hypertens, ; 30 ():0263-6352; 217-26",DALY,United Kingdom,Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Targeted dietary advice & average 5 mmHg reduction in systolic blood pressure (SBP) vs. Standard/Usual Care,Not Stated,Not Stated,41 Years,"Female, Male",Full,,3.50,3.50,Not Stated,United Kingdom,2006,Not Stated
28480,Modelling the impact on avoidable cardiovascular disease burden and costs of interventions to lower SBP in the England population,"The burden of disease from cardiovascular disease (CVD) remains significant in England. Blood pressure remains an important risk factor. Health gain through public health measures and improving treatment compliance are potentially likely to be high. We assess the impact of known cost-effective interventions in terms of the avoidable CVD burden and costs by comparing these strategies to the current situation.We modelled avoidable CVD outcomes simulating the English population aged over 16 years with Excel spreadsheets for the current prevention/treatment and following various interventions over a 10-year time frame. The outcome measures were avoidable incident heart disease and stroke events, deaths and disability-adjusted life years (DALYs). Costs are reported from the health service perspective. We analysed relative cost-effectiveness, undertook sensitivity analysis and measured relative impacts of different strategies on avoidable burden of disease.The assessed interventions have a potential to reduce the current burden of disease between 70?000 and about 1?million DALYs over the 10-year frame. Although all interventions were cost-effective, some (e.g. Salt reduction in the population and 'Dietary Approaches to Stop Hypertension-sodium', which modelled the impact of salt reduction and dietary approaches) were cost-saving. The cost-effectiveness of treatment strategies was sensitive to drug costs.Evidence-based interventions appropriately scaled up for both prevention and treatment of blood pressure lead to important additional potential health gains. There was noticeable variance in cost-effectiveness and impact among the different interventions at a population level. Taking into account impact, priority should be given to prevention to reduce blood pressure at a population level through reduced salt consumption.",2011-99-08289,22080224,J Hypertens,Hiten Dodhia,2012,30 /,217-26,No,22080224,"Hiten Dodhia; Karen Phillips; Maria-Irini Zannou; Mara Airoldi; Gwyn Bevan; Modelling the impact on avoidable cardiovascular disease burden and costs of interventions to lower SBP in the England population, J Hypertens, ; 30 ():0263-6352; 217-26",DALY,United Kingdom,Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Targeted dietary advice with salt reduction & average 10 mmHg reduction in systolic blood pressure (SBP) vs. Standard/Usual Care,Not Stated,Not Stated,41 Years,"Female, Male",Full,,3.50,3.50,Not Stated,United Kingdom,2006,Not Stated
28481,Modelling the impact on avoidable cardiovascular disease burden and costs of interventions to lower SBP in the England population,"The burden of disease from cardiovascular disease (CVD) remains significant in England. Blood pressure remains an important risk factor. Health gain through public health measures and improving treatment compliance are potentially likely to be high. We assess the impact of known cost-effective interventions in terms of the avoidable CVD burden and costs by comparing these strategies to the current situation.We modelled avoidable CVD outcomes simulating the English population aged over 16 years with Excel spreadsheets for the current prevention/treatment and following various interventions over a 10-year time frame. The outcome measures were avoidable incident heart disease and stroke events, deaths and disability-adjusted life years (DALYs). Costs are reported from the health service perspective. We analysed relative cost-effectiveness, undertook sensitivity analysis and measured relative impacts of different strategies on avoidable burden of disease.The assessed interventions have a potential to reduce the current burden of disease between 70?000 and about 1?million DALYs over the 10-year frame. Although all interventions were cost-effective, some (e.g. Salt reduction in the population and 'Dietary Approaches to Stop Hypertension-sodium', which modelled the impact of salt reduction and dietary approaches) were cost-saving. The cost-effectiveness of treatment strategies was sensitive to drug costs.Evidence-based interventions appropriately scaled up for both prevention and treatment of blood pressure lead to important additional potential health gains. There was noticeable variance in cost-effectiveness and impact among the different interventions at a population level. Taking into account impact, priority should be given to prevention to reduce blood pressure at a population level through reduced salt consumption.",2011-99-08289,22080224,J Hypertens,Hiten Dodhia,2012,30 /,217-26,No,22080224,"Hiten Dodhia; Karen Phillips; Maria-Irini Zannou; Mara Airoldi; Gwyn Bevan; Modelling the impact on avoidable cardiovascular disease burden and costs of interventions to lower SBP in the England population, J Hypertens, ; 30 ():0263-6352; 217-26",DALY,United Kingdom,Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Targeted dietary advice with salt reduction & average 10 mmHg reduction in systolic blood pressure (SBP) vs. Standard/Usual Care,Not Stated,Not Stated,41 Years,"Female, Male",Full,,3.50,3.50,Not Stated,United Kingdom,2006,Not Stated
28482,Modelling the impact on avoidable cardiovascular disease burden and costs of interventions to lower SBP in the England population,"The burden of disease from cardiovascular disease (CVD) remains significant in England. Blood pressure remains an important risk factor. Health gain through public health measures and improving treatment compliance are potentially likely to be high. We assess the impact of known cost-effective interventions in terms of the avoidable CVD burden and costs by comparing these strategies to the current situation.We modelled avoidable CVD outcomes simulating the English population aged over 16 years with Excel spreadsheets for the current prevention/treatment and following various interventions over a 10-year time frame. The outcome measures were avoidable incident heart disease and stroke events, deaths and disability-adjusted life years (DALYs). Costs are reported from the health service perspective. We analysed relative cost-effectiveness, undertook sensitivity analysis and measured relative impacts of different strategies on avoidable burden of disease.The assessed interventions have a potential to reduce the current burden of disease between 70?000 and about 1?million DALYs over the 10-year frame. Although all interventions were cost-effective, some (e.g. Salt reduction in the population and 'Dietary Approaches to Stop Hypertension-sodium', which modelled the impact of salt reduction and dietary approaches) were cost-saving. The cost-effectiveness of treatment strategies was sensitive to drug costs.Evidence-based interventions appropriately scaled up for both prevention and treatment of blood pressure lead to important additional potential health gains. There was noticeable variance in cost-effectiveness and impact among the different interventions at a population level. Taking into account impact, priority should be given to prevention to reduce blood pressure at a population level through reduced salt consumption.",2011-99-08289,22080224,J Hypertens,Hiten Dodhia,2012,30 /,217-26,No,22080224,"Hiten Dodhia; Karen Phillips; Maria-Irini Zannou; Mara Airoldi; Gwyn Bevan; Modelling the impact on avoidable cardiovascular disease burden and costs of interventions to lower SBP in the England population, J Hypertens, ; 30 ():0263-6352; 217-26",DALY,United Kingdom,Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Targeted dietary advice with salt reduction & average 10 mmHg reduction in systolic blood pressure (SBP) vs. Standard/Usual Care,Not Stated,Not Stated,41 Years,"Female, Male",Full,,3.50,3.50,Not Stated,United Kingdom,2006,Not Stated
28483,Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support.,"Aims: To examine the cost-effectiveness of personal smoking cessation support in Vietnam. Design, setting and participants: We followed up the population aged 15 and over in 2006 to model the costs and health gains associated with five interventions: physician brief advice; nicotine replacement therapy (patch and gum); Bupropion; and Varenicline. Threshold analysis was undertaken to determine the price levels of pharmaceuticals for the interventions to be cost-effective. A multi-state life table model was constructed such that the interventions affect the smoking cessation behaviour of the age cohorts, and the resulting smoking prevalence defines their health outcomes. A healthcare perspective was employed. Measurements: Cost-effectiveness is measured in 2006 Vietnamese Dong (VND) per disability-adjusted life year (DALY) averted. We adopted the WHO thresholds of being ""cost-effective"" if less than 3 times GDP per capita (VND 34,600,000) and ""very cost-effective"" if less than GDP per capita (VND 11,500,000). Findings: The cost-effectiveness result of physician brief advice was VND 1,583,000 per DALY averted (Int. $493), which was ""very cost-effective"". Varenicline dominated Bupropion and nicotine-replacement therapies, although it did not fall within the range of being ""cost-effective"" under different scenarios. The threshold analysis revealed that prices of pharmaceuticals must be substantially lower than the levels from other countries if pharmacological therapies are to be cost-effective in Vietnam. Conclusions: Physician brief advice is a cost-effective intervention and should be included in the priority list of tobacco control policy in Vietnam. Pharmacological therapies are not cost-effective, and so they are not recommended in Vietnam at this time unless pharmaceuticals would be produced locally at substantially lower costs in the future.",2011-99-07854,21883602,Addiction,Hideki Higashi,2011,/,,No,21883602,"Hideki Higashi; Jan J Barendregt; Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support., Addiction, ; ():0965-2140",DALY,Viet Nam,Not Stated,"Health Education or Behavior, Pharmaceutical",Brief smoking cessation advice vs. None,Not Stated,Not Stated,12 Years,"Female, Male",Full,,3.00,3.00,1742000,Vietnam,2006,139.88
28484,Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support.,"Aims: To examine the cost-effectiveness of personal smoking cessation support in Vietnam. Design, setting and participants: We followed up the population aged 15 and over in 2006 to model the costs and health gains associated with five interventions: physician brief advice; nicotine replacement therapy (patch and gum); Bupropion; and Varenicline. Threshold analysis was undertaken to determine the price levels of pharmaceuticals for the interventions to be cost-effective. A multi-state life table model was constructed such that the interventions affect the smoking cessation behaviour of the age cohorts, and the resulting smoking prevalence defines their health outcomes. A healthcare perspective was employed. Measurements: Cost-effectiveness is measured in 2006 Vietnamese Dong (VND) per disability-adjusted life year (DALY) averted. We adopted the WHO thresholds of being ""cost-effective"" if less than 3 times GDP per capita (VND 34,600,000) and ""very cost-effective"" if less than GDP per capita (VND 11,500,000). Findings: The cost-effectiveness result of physician brief advice was VND 1,583,000 per DALY averted (Int. $493), which was ""very cost-effective"". Varenicline dominated Bupropion and nicotine-replacement therapies, although it did not fall within the range of being ""cost-effective"" under different scenarios. The threshold analysis revealed that prices of pharmaceuticals must be substantially lower than the levels from other countries if pharmacological therapies are to be cost-effective in Vietnam. Conclusions: Physician brief advice is a cost-effective intervention and should be included in the priority list of tobacco control policy in Vietnam. Pharmacological therapies are not cost-effective, and so they are not recommended in Vietnam at this time unless pharmaceuticals would be produced locally at substantially lower costs in the future.",2011-99-07854,21883602,Addiction,Hideki Higashi,2011,/,,No,21883602,"Hideki Higashi; Jan J Barendregt; Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support., Addiction, ; ():0965-2140",DALY,Viet Nam,Not Stated,"Health Education or Behavior, Pharmaceutical",Brief smoking cessation advice + Varenicline vs. None,Not Stated,Not Stated,12 Years,"Female, Male",Full,,3.00,3.00,41561,Vietnam,2006,3.34
28485,Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support.,"Aims: To examine the cost-effectiveness of personal smoking cessation support in Vietnam. Design, setting and participants: We followed up the population aged 15 and over in 2006 to model the costs and health gains associated with five interventions: physician brief advice; nicotine replacement therapy (patch and gum); Bupropion; and Varenicline. Threshold analysis was undertaken to determine the price levels of pharmaceuticals for the interventions to be cost-effective. A multi-state life table model was constructed such that the interventions affect the smoking cessation behaviour of the age cohorts, and the resulting smoking prevalence defines their health outcomes. A healthcare perspective was employed. Measurements: Cost-effectiveness is measured in 2006 Vietnamese Dong (VND) per disability-adjusted life year (DALY) averted. We adopted the WHO thresholds of being ""cost-effective"" if less than 3 times GDP per capita (VND 34,600,000) and ""very cost-effective"" if less than GDP per capita (VND 11,500,000). Findings: The cost-effectiveness result of physician brief advice was VND 1,583,000 per DALY averted (Int. $493), which was ""very cost-effective"". Varenicline dominated Bupropion and nicotine-replacement therapies, although it did not fall within the range of being ""cost-effective"" under different scenarios. The threshold analysis revealed that prices of pharmaceuticals must be substantially lower than the levels from other countries if pharmacological therapies are to be cost-effective in Vietnam. Conclusions: Physician brief advice is a cost-effective intervention and should be included in the priority list of tobacco control policy in Vietnam. Pharmacological therapies are not cost-effective, and so they are not recommended in Vietnam at this time unless pharmaceuticals would be produced locally at substantially lower costs in the future.",2011-99-07854,21883602,Addiction,Hideki Higashi,2011,/,,No,21883602,"Hideki Higashi; Jan J Barendregt; Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support., Addiction, ; ():0965-2140",DALY,Viet Nam,Not Stated,"Health Education or Behavior, Pharmaceutical",Brief smoking cessation advice + Bupropion vs. None,Not Stated,Not Stated,12 Years,"Female, Male",Full,,3.00,3.00,27760,Vietnam,2006,2.23
28486,Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support.,"Aims: To examine the cost-effectiveness of personal smoking cessation support in Vietnam. Design, setting and participants: We followed up the population aged 15 and over in 2006 to model the costs and health gains associated with five interventions: physician brief advice; nicotine replacement therapy (patch and gum); Bupropion; and Varenicline. Threshold analysis was undertaken to determine the price levels of pharmaceuticals for the interventions to be cost-effective. A multi-state life table model was constructed such that the interventions affect the smoking cessation behaviour of the age cohorts, and the resulting smoking prevalence defines their health outcomes. A healthcare perspective was employed. Measurements: Cost-effectiveness is measured in 2006 Vietnamese Dong (VND) per disability-adjusted life year (DALY) averted. We adopted the WHO thresholds of being ""cost-effective"" if less than 3 times GDP per capita (VND 34,600,000) and ""very cost-effective"" if less than GDP per capita (VND 11,500,000). Findings: The cost-effectiveness result of physician brief advice was VND 1,583,000 per DALY averted (Int. $493), which was ""very cost-effective"". Varenicline dominated Bupropion and nicotine-replacement therapies, although it did not fall within the range of being ""cost-effective"" under different scenarios. The threshold analysis revealed that prices of pharmaceuticals must be substantially lower than the levels from other countries if pharmacological therapies are to be cost-effective in Vietnam. Conclusions: Physician brief advice is a cost-effective intervention and should be included in the priority list of tobacco control policy in Vietnam. Pharmacological therapies are not cost-effective, and so they are not recommended in Vietnam at this time unless pharmaceuticals would be produced locally at substantially lower costs in the future.",2011-99-07854,21883602,Addiction,Hideki Higashi,2011,/,,No,21883602,"Hideki Higashi; Jan J Barendregt; Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support., Addiction, ; ():0965-2140",DALY,Viet Nam,Not Stated,"Health Education or Behavior, Pharmaceutical",Nicotine replacement therapy (gum) for smoking cessation vs. None,Not Stated,Not Stated,12 Years,"Female, Male",Full,,3.00,3.00,107826,Vietnam,2006,8.66
28487,Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support.,"Aims: To examine the cost-effectiveness of personal smoking cessation support in Vietnam. Design, setting and participants: We followed up the population aged 15 and over in 2006 to model the costs and health gains associated with five interventions: physician brief advice; nicotine replacement therapy (patch and gum); Bupropion; and Varenicline. Threshold analysis was undertaken to determine the price levels of pharmaceuticals for the interventions to be cost-effective. A multi-state life table model was constructed such that the interventions affect the smoking cessation behaviour of the age cohorts, and the resulting smoking prevalence defines their health outcomes. A healthcare perspective was employed. Measurements: Cost-effectiveness is measured in 2006 Vietnamese Dong (VND) per disability-adjusted life year (DALY) averted. We adopted the WHO thresholds of being ""cost-effective"" if less than 3 times GDP per capita (VND 34,600,000) and ""very cost-effective"" if less than GDP per capita (VND 11,500,000). Findings: The cost-effectiveness result of physician brief advice was VND 1,583,000 per DALY averted (Int. $493), which was ""very cost-effective"". Varenicline dominated Bupropion and nicotine-replacement therapies, although it did not fall within the range of being ""cost-effective"" under different scenarios. The threshold analysis revealed that prices of pharmaceuticals must be substantially lower than the levels from other countries if pharmacological therapies are to be cost-effective in Vietnam. Conclusions: Physician brief advice is a cost-effective intervention and should be included in the priority list of tobacco control policy in Vietnam. Pharmacological therapies are not cost-effective, and so they are not recommended in Vietnam at this time unless pharmaceuticals would be produced locally at substantially lower costs in the future.",2011-99-07854,21883602,Addiction,Hideki Higashi,2011,/,,No,21883602,"Hideki Higashi; Jan J Barendregt; Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support., Addiction, ; ():0965-2140",DALY,Viet Nam,Not Stated,"Health Education or Behavior, Pharmaceutical",Bupropion for smoking cessation vs. None,Not Stated,Not Stated,12 Years,"Female, Male",Full,,3.00,3.00,55854,Vietnam,2006,4.49
28488,Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support.,"Aims: To examine the cost-effectiveness of personal smoking cessation support in Vietnam. Design, setting and participants: We followed up the population aged 15 and over in 2006 to model the costs and health gains associated with five interventions: physician brief advice; nicotine replacement therapy (patch and gum); Bupropion; and Varenicline. Threshold analysis was undertaken to determine the price levels of pharmaceuticals for the interventions to be cost-effective. A multi-state life table model was constructed such that the interventions affect the smoking cessation behaviour of the age cohorts, and the resulting smoking prevalence defines their health outcomes. A healthcare perspective was employed. Measurements: Cost-effectiveness is measured in 2006 Vietnamese Dong (VND) per disability-adjusted life year (DALY) averted. We adopted the WHO thresholds of being ""cost-effective"" if less than 3 times GDP per capita (VND 34,600,000) and ""very cost-effective"" if less than GDP per capita (VND 11,500,000). Findings: The cost-effectiveness result of physician brief advice was VND 1,583,000 per DALY averted (Int. $493), which was ""very cost-effective"". Varenicline dominated Bupropion and nicotine-replacement therapies, although it did not fall within the range of being ""cost-effective"" under different scenarios. The threshold analysis revealed that prices of pharmaceuticals must be substantially lower than the levels from other countries if pharmacological therapies are to be cost-effective in Vietnam. Conclusions: Physician brief advice is a cost-effective intervention and should be included in the priority list of tobacco control policy in Vietnam. Pharmacological therapies are not cost-effective, and so they are not recommended in Vietnam at this time unless pharmaceuticals would be produced locally at substantially lower costs in the future.",2011-99-07854,21883602,Addiction,Hideki Higashi,2011,/,,No,21883602,"Hideki Higashi; Jan J Barendregt; Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support., Addiction, ; ():0965-2140",DALY,Viet Nam,Not Stated,"Health Education or Behavior, Pharmaceutical",Nicotine replacement therapy (patch) for smoking cessation vs. None,Not Stated,Not Stated,12 Years,"Female, Male",Full,,3.00,3.00,277069,Vietnam,2006,22.25
28489,Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support.,"Aims: To examine the cost-effectiveness of personal smoking cessation support in Vietnam. Design, setting and participants: We followed up the population aged 15 and over in 2006 to model the costs and health gains associated with five interventions: physician brief advice; nicotine replacement therapy (patch and gum); Bupropion; and Varenicline. Threshold analysis was undertaken to determine the price levels of pharmaceuticals for the interventions to be cost-effective. A multi-state life table model was constructed such that the interventions affect the smoking cessation behaviour of the age cohorts, and the resulting smoking prevalence defines their health outcomes. A healthcare perspective was employed. Measurements: Cost-effectiveness is measured in 2006 Vietnamese Dong (VND) per disability-adjusted life year (DALY) averted. We adopted the WHO thresholds of being ""cost-effective"" if less than 3 times GDP per capita (VND 34,600,000) and ""very cost-effective"" if less than GDP per capita (VND 11,500,000). Findings: The cost-effectiveness result of physician brief advice was VND 1,583,000 per DALY averted (Int. $493), which was ""very cost-effective"". Varenicline dominated Bupropion and nicotine-replacement therapies, although it did not fall within the range of being ""cost-effective"" under different scenarios. The threshold analysis revealed that prices of pharmaceuticals must be substantially lower than the levels from other countries if pharmacological therapies are to be cost-effective in Vietnam. Conclusions: Physician brief advice is a cost-effective intervention and should be included in the priority list of tobacco control policy in Vietnam. Pharmacological therapies are not cost-effective, and so they are not recommended in Vietnam at this time unless pharmaceuticals would be produced locally at substantially lower costs in the future.",2011-99-07854,21883602,Addiction,Hideki Higashi,2011,/,,No,21883602,"Hideki Higashi; Jan J Barendregt; Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support., Addiction, ; ():0965-2140",DALY,Viet Nam,Not Stated,"Health Education or Behavior, Pharmaceutical",Varenicline for smoking cessation vs. None,Not Stated,Not Stated,12 Years,"Female, Male",Full,,3.00,3.00,70018,Vietnam,2006,5.62
28490,Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support.,"Aims: To examine the cost-effectiveness of personal smoking cessation support in Vietnam. Design, setting and participants: We followed up the population aged 15 and over in 2006 to model the costs and health gains associated with five interventions: physician brief advice; nicotine replacement therapy (patch and gum); Bupropion; and Varenicline. Threshold analysis was undertaken to determine the price levels of pharmaceuticals for the interventions to be cost-effective. A multi-state life table model was constructed such that the interventions affect the smoking cessation behaviour of the age cohorts, and the resulting smoking prevalence defines their health outcomes. A healthcare perspective was employed. Measurements: Cost-effectiveness is measured in 2006 Vietnamese Dong (VND) per disability-adjusted life year (DALY) averted. We adopted the WHO thresholds of being ""cost-effective"" if less than 3 times GDP per capita (VND 34,600,000) and ""very cost-effective"" if less than GDP per capita (VND 11,500,000). Findings: The cost-effectiveness result of physician brief advice was VND 1,583,000 per DALY averted (Int. $493), which was ""very cost-effective"". Varenicline dominated Bupropion and nicotine-replacement therapies, although it did not fall within the range of being ""cost-effective"" under different scenarios. The threshold analysis revealed that prices of pharmaceuticals must be substantially lower than the levels from other countries if pharmacological therapies are to be cost-effective in Vietnam. Conclusions: Physician brief advice is a cost-effective intervention and should be included in the priority list of tobacco control policy in Vietnam. Pharmacological therapies are not cost-effective, and so they are not recommended in Vietnam at this time unless pharmaceuticals would be produced locally at substantially lower costs in the future.",2011-99-07854,21883602,Addiction,Hideki Higashi,2011,/,,No,21883602,"Hideki Higashi; Jan J Barendregt; Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support., Addiction, ; ():0965-2140",DALY,Viet Nam,Not Stated,"Health Education or Behavior, Pharmaceutical",Brief smoking cessation advice + Nicotine replacement therapy (patch) vs. None,Not Stated,Not Stated,12 Years,"Female, Male",Full,,3.00,3.00,134202,Vietnam,2006,10.78
28491,Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support.,"Aims: To examine the cost-effectiveness of personal smoking cessation support in Vietnam. Design, setting and participants: We followed up the population aged 15 and over in 2006 to model the costs and health gains associated with five interventions: physician brief advice; nicotine replacement therapy (patch and gum); Bupropion; and Varenicline. Threshold analysis was undertaken to determine the price levels of pharmaceuticals for the interventions to be cost-effective. A multi-state life table model was constructed such that the interventions affect the smoking cessation behaviour of the age cohorts, and the resulting smoking prevalence defines their health outcomes. A healthcare perspective was employed. Measurements: Cost-effectiveness is measured in 2006 Vietnamese Dong (VND) per disability-adjusted life year (DALY) averted. We adopted the WHO thresholds of being ""cost-effective"" if less than 3 times GDP per capita (VND 34,600,000) and ""very cost-effective"" if less than GDP per capita (VND 11,500,000). Findings: The cost-effectiveness result of physician brief advice was VND 1,583,000 per DALY averted (Int. $493), which was ""very cost-effective"". Varenicline dominated Bupropion and nicotine-replacement therapies, although it did not fall within the range of being ""cost-effective"" under different scenarios. The threshold analysis revealed that prices of pharmaceuticals must be substantially lower than the levels from other countries if pharmacological therapies are to be cost-effective in Vietnam. Conclusions: Physician brief advice is a cost-effective intervention and should be included in the priority list of tobacco control policy in Vietnam. Pharmacological therapies are not cost-effective, and so they are not recommended in Vietnam at this time unless pharmaceuticals would be produced locally at substantially lower costs in the future.",2011-99-07854,21883602,Addiction,Hideki Higashi,2011,/,,No,21883602,"Hideki Higashi; Jan J Barendregt; Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support., Addiction, ; ():0965-2140",DALY,Viet Nam,Not Stated,"Health Education or Behavior, Pharmaceutical",Brief smoking cessation advice + Nicotine replacement therapy (gum) vs. None,Not Stated,Not Stated,12 Years,"Female, Male",Full,,3.00,3.00,42803,Vietnam,2006,3.44
28492,The Impact and Cost-effectiveness of Strategies to Detect Drug Resistant Tuberculosis.,"Drug-resistant tuberculosis is a serious emerging problem in many low resource countries. TB control programs are uncertain which drug susceptibility tests (DST) to use and when to test patients. We predicted the potential cost-effectiveness of different DST strategies, in settings with varying prevalence of drug resistance. Using decision analysis, we assessed the cost-effectiveness of conventional and rapid DST for already diagnosed smear positive TB cases. Five different time points were considered for administering DST. Different initial drug resistance and HIV scenarios were also considered. All DST scenarios in the wide range of settings considered were found to be cost-effective. The strategy of performing a rapid DST that detects any form of isoniazid (INH) and rifampicin (RIF) resistance for all patients before the initiation of treatment was predicted to be the most cost-effective strategy. In a setting with moderate drug resistance, the cost per Disability Adjusted Life Year (DALY) gained was as low as $744. Our findings support the rollout of rapid drug susceptibility testing at the moment of diagnosis to detect any form of INH and RIF resistance in all countries with moderate or greater burdens of drug-resistant TB.",2011-99-07780,21828030,Eur Respir J,O Oxlade,2011,/,,No,21828030,"O Oxlade; D Falzon; D Menzies; The Impact and Cost-effectiveness of Strategies to Detect Drug Resistant Tuberculosis., Eur Respir J, ; ():0903-1936",DALY,Not Stated,Not Stated,Diagnostic,Rapid rifampicin (RIF) drug susceptibility test (DST) to detect RIF resistance vs. no drug susceptibility test,high drug resistance setting,Not Stated,Not Stated,"Female, Male",Full,,Not Stated,3.00,562,United States,2010,667.04
28493,The Impact and Cost-effectiveness of Strategies to Detect Drug Resistant Tuberculosis.,"Drug-resistant tuberculosis is a serious emerging problem in many low resource countries. TB control programs are uncertain which drug susceptibility tests (DST) to use and when to test patients. We predicted the potential cost-effectiveness of different DST strategies, in settings with varying prevalence of drug resistance. Using decision analysis, we assessed the cost-effectiveness of conventional and rapid DST for already diagnosed smear positive TB cases. Five different time points were considered for administering DST. Different initial drug resistance and HIV scenarios were also considered. All DST scenarios in the wide range of settings considered were found to be cost-effective. The strategy of performing a rapid DST that detects any form of isoniazid (INH) and rifampicin (RIF) resistance for all patients before the initiation of treatment was predicted to be the most cost-effective strategy. In a setting with moderate drug resistance, the cost per Disability Adjusted Life Year (DALY) gained was as low as $744. Our findings support the rollout of rapid drug susceptibility testing at the moment of diagnosis to detect any form of INH and RIF resistance in all countries with moderate or greater burdens of drug-resistant TB.",2011-99-07780,21828030,Eur Respir J,O Oxlade,2011,/,,No,21828030,"O Oxlade; D Falzon; D Menzies; The Impact and Cost-effectiveness of Strategies to Detect Drug Resistant Tuberculosis., Eur Respir J, ; ():0903-1936",DALY,Not Stated,Not Stated,Diagnostic,Rapid isoniazid and rifampicin (INH&RIF) drug susceptibility test (DST) to detect RIF and INH resistance vs. no drug susceptibility test,high drug resistance setting,Not Stated,Not Stated,"Female, Male",Full,,Not Stated,3.00,499,United States,2010,592.26
28494,The Impact and Cost-effectiveness of Strategies to Detect Drug Resistant Tuberculosis.,"Drug-resistant tuberculosis is a serious emerging problem in many low resource countries. TB control programs are uncertain which drug susceptibility tests (DST) to use and when to test patients. We predicted the potential cost-effectiveness of different DST strategies, in settings with varying prevalence of drug resistance. Using decision analysis, we assessed the cost-effectiveness of conventional and rapid DST for already diagnosed smear positive TB cases. Five different time points were considered for administering DST. Different initial drug resistance and HIV scenarios were also considered. All DST scenarios in the wide range of settings considered were found to be cost-effective. The strategy of performing a rapid DST that detects any form of isoniazid (INH) and rifampicin (RIF) resistance for all patients before the initiation of treatment was predicted to be the most cost-effective strategy. In a setting with moderate drug resistance, the cost per Disability Adjusted Life Year (DALY) gained was as low as $744. Our findings support the rollout of rapid drug susceptibility testing at the moment of diagnosis to detect any form of INH and RIF resistance in all countries with moderate or greater burdens of drug-resistant TB.",2011-99-07780,21828030,Eur Respir J,O Oxlade,2011,/,,No,21828030,"O Oxlade; D Falzon; D Menzies; The Impact and Cost-effectiveness of Strategies to Detect Drug Resistant Tuberculosis., Eur Respir J, ; ():0903-1936",DALY,Not Stated,Not Stated,Diagnostic,Solid drug susceptibility test (DST) to detect rifampicin (RIF) and isoniazid (INH) resistance vs. no drug susceptibility test,high drug resistance setting,Not Stated,Not Stated,"Female, Male",Full,,Not Stated,3.00,742,United States,2010,880.68
28495,The Impact and Cost-effectiveness of Strategies to Detect Drug Resistant Tuberculosis.,"Drug-resistant tuberculosis is a serious emerging problem in many low resource countries. TB control programs are uncertain which drug susceptibility tests (DST) to use and when to test patients. We predicted the potential cost-effectiveness of different DST strategies, in settings with varying prevalence of drug resistance. Using decision analysis, we assessed the cost-effectiveness of conventional and rapid DST for already diagnosed smear positive TB cases. Five different time points were considered for administering DST. Different initial drug resistance and HIV scenarios were also considered. All DST scenarios in the wide range of settings considered were found to be cost-effective. The strategy of performing a rapid DST that detects any form of isoniazid (INH) and rifampicin (RIF) resistance for all patients before the initiation of treatment was predicted to be the most cost-effective strategy. In a setting with moderate drug resistance, the cost per Disability Adjusted Life Year (DALY) gained was as low as $744. Our findings support the rollout of rapid drug susceptibility testing at the moment of diagnosis to detect any form of INH and RIF resistance in all countries with moderate or greater burdens of drug-resistant TB.",2011-99-07780,21828030,Eur Respir J,O Oxlade,2011,/,,No,21828030,"O Oxlade; D Falzon; D Menzies; The Impact and Cost-effectiveness of Strategies to Detect Drug Resistant Tuberculosis., Eur Respir J, ; ():0903-1936",DALY,Not Stated,Not Stated,Diagnostic,Rapid isoniazid and rifampicin (INH&RIF) drug susceptibility test (DST) performed only if smear positive after 5 months of treatment or with relapse after treatment to detect RIF and INH resistance vs. no drug susceptibility test,high drug resistance setting,Not Stated,Not Stated,"Female, Male",Full,,Not Stated,3.00,718,United States,2010,852.2
28496,The Impact and Cost-effectiveness of Strategies to Detect Drug Resistant Tuberculosis.,"Drug-resistant tuberculosis is a serious emerging problem in many low resource countries. TB control programs are uncertain which drug susceptibility tests (DST) to use and when to test patients. We predicted the potential cost-effectiveness of different DST strategies, in settings with varying prevalence of drug resistance. Using decision analysis, we assessed the cost-effectiveness of conventional and rapid DST for already diagnosed smear positive TB cases. Five different time points were considered for administering DST. Different initial drug resistance and HIV scenarios were also considered. All DST scenarios in the wide range of settings considered were found to be cost-effective. The strategy of performing a rapid DST that detects any form of isoniazid (INH) and rifampicin (RIF) resistance for all patients before the initiation of treatment was predicted to be the most cost-effective strategy. In a setting with moderate drug resistance, the cost per Disability Adjusted Life Year (DALY) gained was as low as $744. Our findings support the rollout of rapid drug susceptibility testing at the moment of diagnosis to detect any form of INH and RIF resistance in all countries with moderate or greater burdens of drug-resistant TB.",2011-99-07780,21828030,Eur Respir J,O Oxlade,2011,/,,No,21828030,"O Oxlade; D Falzon; D Menzies; The Impact and Cost-effectiveness of Strategies to Detect Drug Resistant Tuberculosis., Eur Respir J, ; ():0903-1936",DALY,Not Stated,Not Stated,Diagnostic,Rapid isoniazid and rifampicin (INH&RIF) drug susceptibility test (DST) performed only if smear positive after 3 months of treatment to detect RIF and INH resistance vs. no drug susceptibility test,high drug resistance setting,Not Stated,Not Stated,"Female, Male",Full,,Not Stated,3.00,667,United States,2010,791.66
28497,The Impact and Cost-effectiveness of Strategies to Detect Drug Resistant Tuberculosis.,"Drug-resistant tuberculosis is a serious emerging problem in many low resource countries. TB control programs are uncertain which drug susceptibility tests (DST) to use and when to test patients. We predicted the potential cost-effectiveness of different DST strategies, in settings with varying prevalence of drug resistance. Using decision analysis, we assessed the cost-effectiveness of conventional and rapid DST for already diagnosed smear positive TB cases. Five different time points were considered for administering DST. Different initial drug resistance and HIV scenarios were also considered. All DST scenarios in the wide range of settings considered were found to be cost-effective. The strategy of performing a rapid DST that detects any form of isoniazid (INH) and rifampicin (RIF) resistance for all patients before the initiation of treatment was predicted to be the most cost-effective strategy. In a setting with moderate drug resistance, the cost per Disability Adjusted Life Year (DALY) gained was as low as $744. Our findings support the rollout of rapid drug susceptibility testing at the moment of diagnosis to detect any form of INH and RIF resistance in all countries with moderate or greater burdens of drug-resistant TB.",2011-99-07780,21828030,Eur Respir J,O Oxlade,2011,/,,No,21828030,"O Oxlade; D Falzon; D Menzies; The Impact and Cost-effectiveness of Strategies to Detect Drug Resistant Tuberculosis., Eur Respir J, ; ():0903-1936",DALY,Not Stated,Not Stated,Diagnostic,Rapid isoniazid and rifampicin (INH&RIF) drug susceptibility test (DST) performed only if smear positive after 2 months of treatment to detect RIF and INH resistance vs. no drug susceptibility test,high drug resistance setting,Not Stated,Not Stated,"Female, Male",Full,,Not Stated,3.00,640,United States,2010,759.62
28498,The Impact and Cost-effectiveness of Strategies to Detect Drug Resistant Tuberculosis.,"Drug-resistant tuberculosis is a serious emerging problem in many low resource countries. TB control programs are uncertain which drug susceptibility tests (DST) to use and when to test patients. We predicted the potential cost-effectiveness of different DST strategies, in settings with varying prevalence of drug resistance. Using decision analysis, we assessed the cost-effectiveness of conventional and rapid DST for already diagnosed smear positive TB cases. Five different time points were considered for administering DST. Different initial drug resistance and HIV scenarios were also considered. All DST scenarios in the wide range of settings considered were found to be cost-effective. The strategy of performing a rapid DST that detects any form of isoniazid (INH) and rifampicin (RIF) resistance for all patients before the initiation of treatment was predicted to be the most cost-effective strategy. In a setting with moderate drug resistance, the cost per Disability Adjusted Life Year (DALY) gained was as low as $744. Our findings support the rollout of rapid drug susceptibility testing at the moment of diagnosis to detect any form of INH and RIF resistance in all countries with moderate or greater burdens of drug-resistant TB.",2011-99-07780,21828030,Eur Respir J,O Oxlade,2011,/,,No,21828030,"O Oxlade; D Falzon; D Menzies; The Impact and Cost-effectiveness of Strategies to Detect Drug Resistant Tuberculosis., Eur Respir J, ; ():0903-1936",DALY,Not Stated,Not Stated,Diagnostic,Rapid isoniazid and rifampicin (INH&RIF) drug susceptibility test (DST) performed only if smear positive after 5 months of treatment to detect RIF and INH resistance vs. no drug susceptibility test,high drug resistance setting,Not Stated,Not Stated,"Female, Male",Full,,Not Stated,3.00,735,United States,2010,872.37
28499,The Impact and Cost-effectiveness of Strategies to Detect Drug Resistant Tuberculosis.,"Drug-resistant tuberculosis is a serious emerging problem in many low resource countries. TB control programs are uncertain which drug susceptibility tests (DST) to use and when to test patients. We predicted the potential cost-effectiveness of different DST strategies, in settings with varying prevalence of drug resistance. Using decision analysis, we assessed the cost-effectiveness of conventional and rapid DST for already diagnosed smear positive TB cases. Five different time points were considered for administering DST. Different initial drug resistance and HIV scenarios were also considered. All DST scenarios in the wide range of settings considered were found to be cost-effective. The strategy of performing a rapid DST that detects any form of isoniazid (INH) and rifampicin (RIF) resistance for all patients before the initiation of treatment was predicted to be the most cost-effective strategy. In a setting with moderate drug resistance, the cost per Disability Adjusted Life Year (DALY) gained was as low as $744. Our findings support the rollout of rapid drug susceptibility testing at the moment of diagnosis to detect any form of INH and RIF resistance in all countries with moderate or greater burdens of drug-resistant TB.",2011-99-07780,21828030,Eur Respir J,O Oxlade,2011,/,,No,21828030,"O Oxlade; D Falzon; D Menzies; The Impact and Cost-effectiveness of Strategies to Detect Drug Resistant Tuberculosis., Eur Respir J, ; ():0903-1936",DALY,Not Stated,Not Stated,Diagnostic,Solid drug susceptibility test (DST) to detect rifampicin (RIF) and isoniazid (INH) resistance vs. no drug susceptibility test,moderate drug resistance setting,Not Stated,Not Stated,"Female, Male",Full,,Not Stated,3.00,1135,United States,2010,1347.13
28500,The Impact and Cost-effectiveness of Strategies to Detect Drug Resistant Tuberculosis.,"Drug-resistant tuberculosis is a serious emerging problem in many low resource countries. TB control programs are uncertain which drug susceptibility tests (DST) to use and when to test patients. We predicted the potential cost-effectiveness of different DST strategies, in settings with varying prevalence of drug resistance. Using decision analysis, we assessed the cost-effectiveness of conventional and rapid DST for already diagnosed smear positive TB cases. Five different time points were considered for administering DST. Different initial drug resistance and HIV scenarios were also considered. All DST scenarios in the wide range of settings considered were found to be cost-effective. The strategy of performing a rapid DST that detects any form of isoniazid (INH) and rifampicin (RIF) resistance for all patients before the initiation of treatment was predicted to be the most cost-effective strategy. In a setting with moderate drug resistance, the cost per Disability Adjusted Life Year (DALY) gained was as low as $744. Our findings support the rollout of rapid drug susceptibility testing at the moment of diagnosis to detect any form of INH and RIF resistance in all countries with moderate or greater burdens of drug-resistant TB.",2011-99-07780,21828030,Eur Respir J,O Oxlade,2011,/,,No,21828030,"O Oxlade; D Falzon; D Menzies; The Impact and Cost-effectiveness of Strategies to Detect Drug Resistant Tuberculosis., Eur Respir J, ; ():0903-1936",DALY,Not Stated,Not Stated,Diagnostic,Rapid rifampicin (RIF) drug susceptibility test (DST) to detect RIF resistance vs. no drug susceptibility test,moderate drug resistance setting,Not Stated,Not Stated,"Female, Male",Full,,Not Stated,3.00,935,United States,2010,1109.75
